Original Article
Autologous or Allogeneic Bone Marrow Transplantation Compared with Intensive Chemotherapy in Acute Myelogenous Leukemia
N Engl J Med 1995; 332:217-223January 26, 1995
- Abstract
Background
Allogeneic or autologous bone marrow transplantation and intensive consolidation chemotherapy are used to treat acute myelogenous leukemia in a first complete remission.
Methods
After induction treatment with daunorubicin and cytarabine, patients who had a complete remission received a first course of intensive consolidation chemotherapy, combining intermediate-dose cytarabine and amsacrine. Patients with an HLA-identical sibling were assigned to undergo allogeneic bone marrow transplantation; the others were randomly assigned to undergo autologous bone marrow transplantation (with unpurged bone marrow) or a second course of intensive chemotherapy, combining high-dose cytarabine and daunorubicin. Comparisons were made on the basis of the intention to treat.
Results
A total of 623 patients had a complete remission; 168 were assigned to undergo allogeneic bone marrow transplantation, and 254 were randomly assigned to one of the other two groups. Of these patients, 343 completed the treatment assignment: 144 in the allogeneic-transplantation group, 95 in the autologous-transplantation group, and 104 in the intensive-chemotherapy group. The relapse rate was highest in the intensive-chemotherapy group and lowest in the allogeneic-transplantation group, whereas the mortality rate was highest after allogeneic transplantation and lowest after intensive chemotherapy. The projected rate of disease-free survival at four years was 55 percent for allogeneic transplantation, 48 percent for autologous transplantation, and 30 percent for intensive chemotherapy. However, the overall survival after complete remission was similar in the three groups, since more patients who relapsed after a second course of intensive chemotherapy had a response to subsequent autologous bone marrow transplantation. Other differences were also observed, especially with regard to hematopoietic recovery (it occurred later after autologous transplantation) and the duration of hospitalization (it was longer with bone marrow transplantation).
Conclusions
During first complete remission in acute myelogenous leukemia, autologous as well as allogeneic bone marrow transplantation results in better disease-free survival than intensive consolidation chemotherapy with high-dose cytarabine and daunorubicin. Transplantation soon after a relapse or during a second complete remission might also be appropriate.
Media in This Article
Figure 3
Kaplan–Meier Plots of Overall Survival after a First Complete Remission, According to Whether Patients Were Assigned to an Autologous or Allogeneic Bone Marrow Transplantation (BMT) or a Second Course of Intensive Consolidation Therapy.Figure 1
Design of the Study.Article Activity
- Article
Most patients with primary acute myelogenous leukemia (AML) enter complete remission after induction therapy.1 The majority, however, relapse despite various types of consolidation and maintenance chemotherapy.2,3 Therefore, in adult patients less than 60 years of age, treatment after the initial induction of remission has been progressively intensified.4-8
An increasing number of patients who enter a complete remission are being treated with allogeneic bone marrow transplantation or, more recently, with autologous bone marrow transplantation. Most reports of results with bone marrow transplantation have been from single institutions9-12 or registries13-15 and thus may reflect a selection bias.16,17 The need for prospective studies comparing the treatment options for acute myelogenous leukemia has frequently been emphasized; however, the results of the initial controlled trials comparing allogeneic bone marrow transplantation and chemotherapy18-20 were the subject of controversy.21,22
Autologous bone marrow transplantation using conditioning regimens similar to those first adopted for allogeneic bone marrow transplantation lacks the graft-versus-leukemia effect of the latter method.23 It also carries the risk of reinjecting occult residual leukemic cells. Attempts to avoid this hazard have been made by purging the bone marrow before reinfusion.24 Nevertheless, pilot studies have reported good outcomes at four to five years despite the use of unpurged bone marrow.10,25,26
In 1986 the European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) Leukemia Cooperative Groups decided to conduct a prospective trial of three postremission treatments to examine disease-free survival and overall survival. All patients received an intensive course of consolidation therapy combining intermediate-dose cytarabine and amsacrine. Only patients who had an HLA-identical sibling were allowed to undergo allogeneic bone marrow transplantation.18,19 The remaining patients were randomly assigned to receive either autologous bone marrow transplantation or a second course of intensified chemotherapy consisting of high-dose cytarabine and daunorubicin.
Methods
Patients
Patients with previously untreated acute myelogenous leukemia were eligible for entry into the trial. The diagnosis was made by the participating centers according to the criteria of the French–American–British (FAB) classification system27; it was confirmed by the data center on the basis of the reported cytologic features, especially the presence of Auer bodies, positive staining for myeloperoxidase, or both. A cytology committee reviewed the smears from 66 percent of patients. Patients who were 10 to 45 years of age were eligible, but very few who were younger than 15 years of age were enrolled. Some centers were allowed to include patients 46 to 59 years of age, according to a policy established at the beginning of the trial. Informed consent was obtained according to the regulations of each institution. Patients with chronic myeloid leukemia or other myeloproliferative diseases in blast crisis were excluded, as were patients who had had a myelodysplastic syndrome for more than six months.
The median age of the patients was 33 years (range, 11 to 59), with a ratio of male to female patients of 1.08. The distribution of the morphologic types of AML according to the FAB classification was similar to that in other reports (M0, 0.1 percent; M1, 16.4 percent; M2, 33.3 percent; M3, 7.1 percent; M4, 20 percent; M5, 18.7 percent; M6, 3.9 percent; and M7, 0.6 percent). Some centers from the GIMEMA group excluded patients with acute promyelocytic (M3) leukemia.
Treatment
Figure 1Figure 1
Design of the Study. shows the design of the study. The induction treatment consisted of one course, or in the case of a partial response, two courses, of daunorubicin, at a dose of 45 mg per square meter of body-surface area, given intravenously on days 1, 2, and 3, and cytarabine, at a dose of 200 mg per square meter, given as a continuous intravenous infusion on days 1 through 7.All patients who had a complete remission were scheduled to receive a course of intensive consolidation chemotherapy consisting of intermediate-dose cytarabine (1000 mg per square meter), given as a continuous intravenous infusion over a period of 2 hours every 12 hours on days 1 through 6, and amsacrine, given intravenously at a dose of 120 mg per square meter on days 5, 6, and 7. After the first year of the study, the dose of cytarabine was decreased to 500 mg per square meter; this adjustment reduced the incidence of lethal infections from 8 percent in the first 75 patients to 4.5 percent in the subsequent patients.
Patients with a confirmed complete remission and an HLA-identical sibling willing to act as a donor were scheduled for allogeneic bone marrow transplantation. All remaining patients in complete remission were randomly assigned to undergo autologous bone marrow transplantation or a second course of intensive consolidation chemotherapy. The standard conditioning regimen for both allogeneic and autologous bone marrow transplantation consisted of cyclophosphamide, at a daily dose of 60 mg per kilogram of body weight on two consecutive days, and total-body irradiation, in a single fraction of 10 Gy or in four to six fractions (total, 12 Gy) given over a period of two to three days. In 34 percent of the patients who received an allogeneic transplant and in 55 percent of those who received an autologous transplant, the conditioning regimen combined busulfan at a daily dose of 4 mg per kilogram on days 6 to 3 before transplantation with cyclophosphamide at a daily dose of 60 mg per kilogram on days 2 and 1 before transplantation. Prophylaxis against graft-versus-host disease after allogeneic transplantation consisted mainly of cyclosporine alone or in combination with methotrexate. In 24 of 144 patients (17 percent) the allogeneic marrow was depleted of T cells before transplantation, mainly by elutriation. In patients randomly assigned to undergo autologous bone marrow transplantation, bone marrow was harvested after hematologic recovery from the first course of consolidation chemotherapy in amounts sufficient to collect at least 1×108 nucleated cells per kilogram and at least 1×104 granulocyte–macrophage colony-forming units per kilogram; this bone marrow was cryopreserved without purging in all but six patients from three centers.
Patients who were randomly assigned to a second course of intensive consolidation chemotherapy received high-dose cytarabine (2 g per square meter), given as a continuous infusion over a 2-hour period every 12 hours on days 1, 2, 3, and 4, and daunorubicin, at a dose of 45 mg per square meter on days 5, 6, and 7. The dose of cytarabine was limited to 2 g per square meter to decrease the risk of cerebellar toxicity.28 No hematopoietic growth factor was used.
Statistical Analysis
All patients were prospectively registered at the EORTC Data Center, in Brussels, Belgium. Patients who had a confirmed complete remission after a first course of intensive consolidation chemotherapy and who did not have an HLA-identical sibling were randomly assigned to treatment groups according to the minimization technique,29 in which they were prospectively stratified according to age and center. A total of 243 randomized patients was required to detect a difference of 20 percentage points (30 percent vs. 50 percent) in disease-free survival at three years between patients undergoing autologous bone marrow transplantation and those who received a second course of intensive consolidation chemotherapy. The homogeneity of the treatment groups was tested with the Kruskal–Wallis30 and chi-square29 tests.
Disease-free survival was calculated from the date of the first complete remission until the date of the first relapse or the date of death in first complete remission. The duration of survival after complete remission corresponds to the length of time from the first complete remission to the date of death. Actuarial curves were calculated according to the Kaplan–Meier technique, and the standard error was computed with Greenwood's formula.29 The differences between curves were tested for statistical significance with the two-tailed log-rank test.29 For ordered prognostic factors, the log-rank test for linear trend was used.29 The instantaneous relative risk of an event per unit of time in one treatment group as compared with that in another and its corresponding 95 percent confidence interval were computed with calculations of the log-rank type.31
Even though some patients received treatments other than their assigned ones, all randomized patients and the patients considered eligible for allogeneic bone marrow transplantation were analyzed only in their respective treatment groups in order to adhere to the intention-to-treat principle.
Results
Between November 1986 and April 1993, 990 patients were registered in the study by 59 institutions. Thirty-six patients were ruled ineligible (19 because of an inadequate diagnosis and 17 because they met other exclusion criteria), and 13 patients could not be evaluated because of missing data. Thus, a total of 941 patients were evaluated. As of November 1993 the median follow-up was 3.3 years.
A complete remission was achieved in 623 patients (66 percent), 576 of whom received the first course of intensive consolidation chemotherapy. An HLA-matched sibling was identified for 230 of the 623 patients who entered complete remission, and 168 of those patients were assigned to undergo allogeneic bone marrow transplantation, 4 directly after entering a complete remission and 164 after the first course of consolidation chemotherapy. Of the remaining patients, 254 underwent randomization: 128 to autologous bone marrow transplantation and 126 to a second course of intensive consolidation chemotherapy. The number of patients who completed their assigned treatment was 144 in the group assigned to allogeneic transplantation, 95 in the group assigned to autologous transplantation, and 104 in the group assigned to intensive chemotherapy. Table 1Table 1
Reasons for Not Completing the Protocol as Scheduled at Each Step among Patients Who Entered a First Complete Remission. shows the main reasons for not carrying out allogeneic bone marrow transplantation or randomization or completing the treatment. Toxicity was a notable cause of exclusion, especially after the first course of intensive chemotherapy. Refusal to receive the assigned treatment was less common among patients assigned to allogeneic transplantation than among those randomly assigned to autologous transplantation or intensive chemotherapy.Protocol violations also occurred, whether instituted by a physician or a patient. Thus, in addition to early relapses or deaths and 2 patients lost to follow-up, 39 patients who were assigned to one of the three treatment groups did not complete the protocol as scheduled. Some of them completed a treatment different from the one planned: of the patients randomly assigned to a second course of intensive consolidation chemotherapy, five underwent autologous bone marrow transplantation and one allogeneic transplantation. Of the patients randomly assigned to undergo autologous bone marrow transplantation, five received a second course of intensive consolidation chemotherapy and two underwent allogeneic transplantation. One of the patients scheduled for allogeneic bone marrow transplantation instead received intensive chemotherapy. Nevertheless, patients were kept in their assigned groups for the analysis of results.
The median length of time between the achievement of complete remission and the initiation of the last treatment step differed significantly among the three treatment groups: 10 weeks in the intensive-chemotherapy group, 14 weeks in the autologous-transplantation group, and 15 weeks in the allogeneic-transplantation group (P<0.001). The number of early relapses consequently differed between the three groups: 5 in the intensive-chemotherapy group, 12 in the autologous-transplantation group, and 18 in the allogeneic-transplantation group. The delays in treatment were principally due to delays at the transplantation centers and to the time required to assess colony growth in vitro in the case of autologous transplantation. Four patients randomly assigned to autologous transplantation and 10 assigned to allogeneic transplantation had an early relapse and were treated at relapse or after entering a second complete remission.
Table 2Table 2
Characteristics of the Patients in Each Treatment Group. shows the characteristics of the patients in the three groups. Univariate analyses of disease-free survival revealed several adverse prognostic factors: an FAB class other than M2 or M3 (P<0.001), a longer interval from diagnosis to complete remission (P<0.001), the need for more than one course of induction chemotherapy to achieve a complete remission (P = 0.003), a poor or intermediate prognosis according to the cytogenetic classification of Keating et al.32 (P = 0.002), a high white-cell count (P = 0.002), and an elevated serum lactate dehydrogenase concentration (P = 0.03). These prognostic factors were evenly distributed among the three groups. All patients scheduled for allogeneic transplantation were 45 years of age or younger, whereas 10 patients assigned to intensive chemotherapy and 9 patients assigned to undergo autologous transplantation were 46 to 59 years of age. In this study, age (10 to 59 years) was not a prognostic factor for disease-free survival.Table 3Table 3
Incidence of Death or Relapse of AML among 623 Patients with a First Complete Remission. shows the incidence of death or relapse of AML as a first event for all patients who entered complete remission. Most relapses occurred in bone marrow, but 10.5 percent were extramedullary (central nervous system or cutaneous), occurring either alone or in combination with a relapse affecting bone marrow. The crude relapse rate was higher in the intensive-chemotherapy group (57.1 percent) than in the autologous-transplantation group (40.6 percent) or the allogeneic-transplantation group (24.4 percent). The respective death rates in the three groups were 7.1 percent, 9.4 percent, and 17.3 percent. The crude death rates among patients who were in a first complete remission, classified according to the treatment actually received, were 5.8 percent in the intensive-chemotherapy group (6 of 104 patients), 10.4 percent in the autologous-transplantation group (10 of 96 patients), and 20 percent in the allogeneic-transplantation group (29 of 145 patients).Figure 2Figure 2
Kaplan–Meier Plots of Disease-free Survival, According to Whether Patients Were Assigned to Autologous or Allogeneic Bone Marrow Transplantation (BMT) or a Second Course of Intensive Consolidation Therapy. shows the probability of disease-free survival in the three groups and the projected rates (±SE) at four years for intensive chemotherapy (30±4 percent), autologous transplantation (48±5 percent), and allogeneic transplantation (55±4 percent). A comparison of disease-free survival in the autologous-transplantation group with that in the intensive-chemotherapy group yielded a relative risk of death or relapse of 0.73 (95 percent confidence interval, 0.52 to 1.00) and a P value of 0.05 (by the log-rank test). Restricting the analysis to the 235 randomized patients who were 45 years of age or younger yielded similar results (P = 0.04). For exploratory purposes, additional analyses were made, with an appreciation for potential sources of bias (especially with respect to the regimen of bone marrow transplantation preferred by the various centers). Disease-free survival was not influenced by the type of conditioning regimen used (with or without total-body irradiation) for engraftment. The influence of the method of preventing graft-versus-host disease after allografting (methotrexate plus cyclosporine vs. cyclosporine alone) was almost significant (P = 0.06).Figure 3Figure 3
Kaplan–Meier Plots of Overall Survival after a First Complete Remission, According to Whether Patients Were Assigned to an Autologous or Allogeneic Bone Marrow Transplantation (BMT) or a Second Course of Intensive Consolidation Therapy. shows overall survival after a complete remission according to the intended treatment. There were no significant differences among the three groups. A higher incidence of early mortality after allogeneic transplantation was counterbalanced by a lower incidence of late mortality in that group. At four years the estimated rate of overall survival was 46±5 percent for the intensive-chemotherapy group, 56±5 percent for the autologous-transplantation group, and 59±4 percent for the allogeneic-transplantation group. The difference in survival between the two randomized groups was not significant (P = 0.43 by the log-rank test; relative risk, 0.86; 95 percent confidence interval, 0.59 to 1.25).Among the patients who relapsed after completing the assigned treatment and received reinduction chemotherapy, those given a second course of intensive consolidation chemotherapy had the highest proportion of second complete remissions (Table 4Table 4
Number of Patients Completing Their Assigned Treatment Who, after Relapse and Reinduction, Had a Second Complete Remission and Subsequently Underwent Allogeneic or Autologous Bone Marrow Transplantation.). Many of them (22 of 36) subsequently underwent autologous bone marrow transplantation, frequently with bone marrow harvested during the first complete remission. By contrast, the rate at which a second bone marrow transplantation was performed after a relapse in the groups that underwent either allogeneic or autologous transplantation was low.Table 5Table 5
Pairwise Comparisons of the Estimates of Relative Risk with Respect to the Time to First Relapse and Time to Death in First Complete Remission. shows pairwise comparisons of the estimates of the relative risk of relapse after treatment allocation and of death after the completion of the assigned treatment. The risk of relapse was highest in the intensive-chemotherapy group, followed by autologous transplantation and then by allogeneic transplantation, despite the higher number of early relapses in patients assigned to transplantation. When the relative risk of death after the completion of treatment was ranked, allogeneic transplantation was first, followed by autologous transplantation and then by intensive chemotherapy.Other differences were observed among the three groups. The length of time to hematopoietic recovery was significantly longer after autologous transplantation than after allogeneic transplantation or intensive chemotherapy; the median time for the absolute granulocyte count to return to at least 1000 per cubic millimeter was 6, 3, and 3 weeks after autologous transplantation, allogeneic transplantation, and intensive chemotherapy, respectively, and the median time for the platelet count to return to at least 100,000 per cubic millimeter was more than 20, 7, and 6 weeks, respectively (P<0.001). The duration of hospitalization was longer (P<0.001) for autologous and allogeneic transplantation than for consolidation chemotherapy (median days of hospitalization, 45, 40, and 28, respectively; P<0.001).
Discussion
Our study confirms reports from single centers or registries10,14,33 that autologous bone marrow transplantation, performed during a first complete remission of AML, results in a disease-free survival of approximately 50 percent at four years. This result was obtained even though the bone marrow was not purged in most cases. Either autologous or allogeneic bone marrow transplantation resulted in an apparently longer disease-free survival than a short course of consolidation chemotherapy. However, the estimated overall survival at four years was similar in the three treatment groups.
Studies intended to assess these types of postremission treatment in AML19,34-36 are frequently criticized for having limited numbers of patients or selection biases or for failing to use intention-to-treat analysis. Like a few other prospective studies, the present one was designed in an attempt to avoid such limitations or biases.19,37 It included a large number of centers and patients, thus allowing a systematic comparison of the three treatment options despite the unavoidable heterogeneity of the transplantation regimens. No patient relapsed more than two years after allogeneic bone marrow transplantation; although the results of autologous bone marrow transplantation appear to be similar, only longer follow-up can reveal the risk of late relapses.
We observed real differences between the groups that underwent allogeneic and autologous bone marrow transplantation: relapses were more frequent among those who underwent autologous transplantation, but the mortality rate was higher among those who underwent allogeneic transplantation. Another consideration is that the conditioning regimens for bone marrow transplantation cause infertility, thus leading some young patients to choose chemotherapy instead.
It has frequently been suggested that patients selected for allogeneic transplantation are young people with good prognostic factors.16,18 In our study, the timing of assignment to allogeneic transplantation varied and depended on the identification of donors and the length of time needed for the patients to recover from the toxic effects of previous treatments. The number of patients who did not complete their assigned treatments was also considerable. Nevertheless, the three groups are comparable and seem to be representative of the typical population of patients with AML in a first complete remission. This conclusion is supported by the number of patients assigned to allogeneic bone marrow transplantation, which is close to the number expected on the basis of genetic chance, and by the even distribution of the main characteristics of the patients who entered the study, particularly features of prognostic value. It is therefore likely that either transplantation regimen was superior to intensive consolidation chemotherapy. However, the advantage of bone marrow transplantation may depend on the type of consolidation chemotherapy selected. Our chemotherapy regimen, which is currently being assessed in a parallel prospective study of patients 46 to 60 years of age,38 could have been suboptimal. In other prospective studies, different regimens of intensive consolidation chemotherapy were superior to conventional regimens37,39 or were equivalent to bone marrow transplantation.37,40,41
In our study the advantage of allogeneic and autologous transplantation over intensive chemotherapy was limited to disease-free survival; neither transplantation regimen significantly improved overall survival. Although a lower rate of death during complete remission in the intensive-chemotherapy group might explain this discrepancy, the difference seems due mainly to the better salvage rates with secondary autologous transplantation in patients who relapsed after chemotherapy. Some authors have therefore suggested restricting transplantation to patients in a first relapse or second complete remission.19,42,43 Only randomized studies can reliably assess the value of this strategy.
Our analysis confirms the prognostic value, in terms of disease-free survival, of some clinical and biologic variables such as the cytogenetic risk group and the time needed to achieve a complete remission. The cytogenetic group has an especially important effect on the outcome of treatment in AML.32 Some authors have suggested adapting treatment to the cytologic and karyotypic pattern of the leukemic cells, but such a specific approach is currently applied only to the promyelocytic subtype of AML, for which tretinoin (all-trans-retinoic acid) is used.44
In our study and in other trials,7,35,40 the large number of patients who did not complete the treatment protocol for various reasons, especially because of a physician's decision or their own wishes, is notable. Such decisions are usually made because of concern about the expected toxicity of the various treatments, which may counterbalance hopes for a cure. Ongoing analyses of the cost effectiveness and quality of life during and after the completion of treatment will have an important bearing on the decision-making process. Together with results regarding the comparative risk of relapse, toxicity, and treatment-related mortality, they will help patients and physicians to choose the best postremission treatment.
Presented in part at the 35th annual meeting of the American Society of Hematology, St. Louis, December 3–7, 1993.
Source Information
From the Departments of Hematology of Hôtel-Dieu, Paris (R.A.Z.); Università La Sapienza, Rome (F.M., M.L.V., M.C.P.); Leiden University, Leiden, the Netherlands (R.W.); St. Radboud Hospital, Nijmegen, the Netherlands (T.W.); Hospital Rebro, Zagreb, Croatia (B.L.); Ospedale Maggiore S.G. Battista, Turin, Italy (L.R.); Università di Firenze, Florence, Italy (F.L.); Ospedale San Martino, Genoa, Italy (E.D.); Istituto L.A. Seragnoli, Università di Bologna, Bologna, Italy (G.V.); Università Tor Vergata, Rome (G.P.); Ospedale Cervello, Palermo, Italy (F.C.); Institut Gustave Roussy, Villejuif, France (M.H.); Institut Jules Bordet, Brussels, Belgium (P.S.); II Università di Napoli, Naples, Italy (B.R.); Università di Ancona, Ancona, Italy (P.L.); University of Antwerp, Antwerp, Belgium (M.E.P.); and the EORTC Data Center, Brussels, Belgium (M.D., G.S., S.S.).
Address reprint requests to Dr. Zittoun at Hôtel-Dieu, 1, Place du Parvis Notre Dame, 75181 Paris Cedex 04, France.
Members of each group who participated in the study are listed in the Appendix.
Appendix
The following centers and investigators from the EORTC Leukemia Cooperative Group participated in this study: Austria: Innsbruck, Universitätsklinik (J. Thaler); Belgium: Antwerpen, University of Antwerpen (M.E. Peetermans); Brugge, Hôpital St. Jan (A. Louwagie); Bruxelles, Institut Bordet (P. Stryckmans), Hôpital Saint Pierre (C. Cauchie), and Hôpital Erasme (W. Ferremans); Verviers, Hôpital Civil (R. Paulus); Croatia: Zagreb, Hospital Rebro (B. Labar), and Novosel School (B. Jaksic); France: Nice, Centre Antoine Lacassagne (A. Thyss); Paris, Hôtel-Dieu (R.A. Zittoun); Suresnes, Centre Foch (E. Baumelou); Villejuif, Institut Gustave Roussy (M. Hayat); the Netherlands: Amsterdam, Onze Lieve Vrouw Gasthuis (K. Roozendaal); Eindhoven, Catharina Ziekenhuis (H. Hillen); Enscheide, Vereniging Ziekenzorg (W. Van Berkel); Hertogenbosch, Groot Ziekenhuis (J. Burghouts); Leiden, Leiden University (R. Willemze); Nijmegen, St. Radboud Hospital (T. de Witte); Portugal: Coimbra, Universidade de Coimbra (G. Teixeira); Porto, San Joan (M. Ribeiro); and Turkey: Ankara, Ibnui Sina Hospital (M.D. Beksac).
The following centers and investigators from the GIMEMA group participated in this study: Italy: Ancona, Università di Ancona (P. Leoni); Avellino, Ospedale Civile (E. Volpe); Aviano, Centro di Riferimento Oncologico (S. Monfardini); Bari, Università di Bari (V. Liso); Bologna, Istituto L.A. Seragnoli (S. Tura, G. Visani, and A. Zaccaria); Cagliari, Ospedale Businco (G. Broccia); Catania, Ospedale Ferrarotto (E. Cacciola); Catanzaro, Ospedale Pugliese (A. Alberti); Cremona, Ospedale Civile 51 (A. Porcellini); Cuneo, Ospedale S. Croce (A. Gallamini); Ferrara, Arcispedale S. Anna (G.L. Castoldi); Firenze, Università di Firenze (P. Rossi Ferrini and F. Leoni); Foggia, Ospedale Riuniti (M. Monaco); Genova, Ospedale S. Martino (E. Damasio); Latina, Ospedale S. Maria Goretti (L. Deriu); Milano, Ospedale Niguarda (F. De Cataldo); Napoli, Ospedale N. Pelligrini (R. De Biasi), II Università (B. Rotoli), and Ospedale Cardarelli (R. Cimino); Nuoro, Ospedale S. Francesco (A. Gabbas); Palermo, Università Policlinico (P. Citarrella), Ospedale Cervello (F. Caronia), and Università di Palermo (A. Cajozzo); Parma, Università (V. Rizzoli); Pavia, Policlinico S. Matteo (C. Bernasconi); Perugia, Università Clinica Medica (F. Grignani), and Università Istituto di Ematologia (M. Martelli); Pesaro, Ospedale S. Salvatore (G. Lucarelli); Pescara, Ospedale Civile (G. Torlontano); Potenza, Ospedale S. Carlo (F. Ricciuti); Reggio Calabria, Ospedale Riuniti (F. Nobile); Roma, II Università Tor Vergata (G. Papa*), I Università La Sapienza (F. Mandelli, W. Arcese, and G. Meloni), Università Cattolica del Sacro Cuore (G. Leone), and Ospedale S. Camillo (A. De Laurenzi); San Giovanni Rotondo, Ospedale Casa Sollievo della Sofferenza (M. Carotenuto); and Torino, Ospedale Maggiore S. Giovanni Battista (L. Resegotti), and Università di Torino (A. Pileri).
Cytology committee: M. Cadiou, M. Bernier, G. Den Ottolander, U. Jehn, W. Sizoo, G.L. Castoldi, S. Fenu, and V. Liso.
Cytogenetic committee: A. Hagemeijer, G. Alimena, A. Bernheim, and A. Zaccaria.
- References
References
1
Stone RM ,Mayer RJ . Treatment of the newly diagnosed adult with de novo acute myeloid leukemia. Hematol Oncol Clin North Am 1993;7:47-64
Web of Science | Medline2
Cassileth PA ,Begg CB ,Bennett JM , et al. A randomized study of the efficacy of consolidation therapy in adult acute nonlymphocytic leukemia. Blood 1984;63:843-847
Web of Science | Medline3
Buchner T ,Urbanitz D ,Hiddemann W , et al. Intensified induction and consolidation with or without maintenance chemotherapy for acute myeloid leukemia (AML): two multicenter studies of the German AML Cooperative Group. J Clin Oncol 1985;3:1583-1589
Web of Science | Medline4
Rohatiner AZ ,Gregory WM ,Bassan R , et al. Short-term therapy for acute myelogenous leukemia. J Clin Oncol 1988;6:218-226
Web of Science | Medline5
Zittoun R ,Jehn U ,Fiere D , et al. Alternating v repeated postremission treatment in adult acute myelogenous leukemia: a randomized phase III study (AML 6) of the EORTC Leukemia Cooperative Group. Blood 1989;73:896-906
Web of Science | Medline6
Wolff SN ,Herzig RH ,Fay JW , et al. High-dose cytarabine and daunorubicin as consolidation therapy for acute myeloid leukemia in first remission: long-term follow-up and results. J Clin Oncol 1989;7:1260-1267
Web of Science | Medline7
Preisler HD ,Raza A ,Early A , et al. Intensive remission consolidation therapy in the treatment of acute nonlymphocytic leukemia. J Clin Oncol 1987;5:722-730
Web of Science | Medline8
Cassileth PA ,Begg CB ,Silber R , et al. Prolonged unmaintained remission after intensive consolidation therapy in adult acute nonlymphocytic leukemia. Cancer Treat Rep 1987;71:137-140
Medline9
Clift RA ,Buckner CD ,Thomas ED , et al. The treatment of acute non-lymphoblastic leukemia by allogeneic marrow transplantation. Bone Marrow Transplant 1987;2:243-258
Web of Science | Medline10
Burnett AK ,Tansey P ,Watkins R , et al. Transplantation of unpurged autologous bone-marrow in acute myeloid leukaemia in first remission. Lancet 1984;2:1068-1070
CrossRef | Web of Science | Medline11
Santos GW ,Tutschka PJ ,Brookmeyer R , et al. Marrow transplantation for acute nonlymphocytic leukemia after treatment with busulfan and cyclophosphamide. N Engl J Med 1983;309:1347-1353
Full Text | Web of Science | Medline12
Willemze R ,Fibbe WE ,Kluin-Nelemans JC , et al. Bone marrow transplantation or chemotherapy as post-remission treatment of adult acute myelogenous leukemia. Ann Hematol 1991;62:59-63
CrossRef | Web of Science | Medline13
International Bone Marrow Transplant Registry
Web of Science | Medline14
Gorin NC ,Aegerter P ,Auvert B , et al. Autologous bone marrow transplantation for acute myelocytic leukemia in first remission: a European survey of the role of marrow purging. Blood 1990;75:1606-1614
Web of Science | Medline15
Hermans J ,Suciu S ,Stijnen T , et al. Treatment of acute myelogenous leukemia: an EBMT-EORTC retrospective analysis of chemotherapy versus allogeneic or autologous bone marrow transplantation. Eur J Cancer Clin Oncol 1989;25:545-550
CrossRef | Medline16
Begg CB ,McGlave PB ,Bennett JM ,Cassileth PA ,Oken MM . A critical comparison of allogeneic bone marrow transplantation and conventional chemotherapy as treatment for acute nonlymphocytic leukemia. J Clin Oncol 1984;2:369-378
Web of Science | Medline17
Suciu S . The value of BMT in AML patients in first remission: a statistician's view-point. Ann Hematol 1991;62:41-44
CrossRef | Web of Science | Medline18
Champlin RE ,Ho WG ,Gale RP , et al. Treatment of acute myelogenous leukemia: a prospective controlled trial of bone marrow transplantation versus consolidation chemotherapy. Ann Intern Med 1985;102:285-291
Web of Science | Medline19
Appelbaum FR ,Fisher LD ,Thomas ED . Chemotherapy v marrow transplantation for adults with acute nonlymphocytic leukemia: a five-year follow-up. Blood 1988;72:179-184
Web of Science | Medline20
Zander AL ,Keating M ,Dicke K , et al. A comparison of marrow transplantation with chemotherapy for adults with acute leukemia of poor prognosis in first complete remission. J Clin Oncol 1988;6:1548-1557
Web of Science | Medline21
Mayer RJ . Allogeneic transplantation versus intensive chemotherapy in first-remission acute leukemia: is there a “best choice“? J Clin Oncol 1988;6:1532-1536
Web of Science | Medline22
Santos GW . Marrow transplantation in acute nonlymphocytic leukemia. Blood 1989;74:901-908
Web of Science | Medline23
Horowitz MM ,Gale RP ,Sondel PM , et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990;75:555-562
Web of Science | Medline24
Gorin NC ,Labopin M ,Meloni G , et al. Autologous bone marrow transplantation for acute myeloblastic leukemia in Europe: further evidence of the role of marrow purging by mafosfamide. Leukemia 1991;5:896-904
Web of Science | Medline25
Goldstone AH ,Anderson CC ,Linch DC , et al. Autologous bone marrow transplantation following high dose chemotherapy for the treatment of adult patients with acute myeloid leukaemia. Br J Haematol 1986;64:529-537
CrossRef | Web of Science | Medline26
Carella AM ,Gaozza E ,Santini M , et al. Autologous unpurged bone marrow transplantation for acute nonlymphoblastic leukaemia in first complete remission. Bone Marrow Transplant 1988;3:537-541
Web of Science | Medline27
Bennett JM ,Catovsky D ,Daniel MT , et al. Proposed revised criteria for the classification of acute myeloid leukemia: a report of the French-American-British Cooperative Group. Ann Intern Med 1985;103:620-625
Web of Science | Medline28
Herzig RH ,Hines JD ,Herzig GP , et al. Cerebellar toxicity with high-dose cytosine arabinoside. J Clin Oncol 1987;5:927-932
Web of Science | Medline29
Buyse ME, Staquet MJ, Sylvester RJ, eds. Cancer clinical trials: methods and practice. Oxford, England: Oxford University Press, 1984:337-406.
30
Kruskal WH ,Wallis WA . Use of ranks in one-criterion variance analysis. J Am Stat Assoc 1952;47:583-621
CrossRef | Web of Science31
Machin D, Gardner MJ. Calculating confidence intervals for survival time analyses. In: Gardner MJ, Altman DF, eds. Statistics with confidence: confidence-intervals and statistical guidelines. London: British Medical Journal, 1989:64-70.
32
Keating MJ ,Smith TL ,Kantarjian H , et al. Cytogenetic pattern in acute myelogenous leukemia: a major reproducible determinant of outcome. Leukemia 1988;2:403-412
Web of Science | Medline33
McMillan AK ,Goldstone AH ,Linch DC , et al. High-dose chemotherapy and autologous bone marrow transplantation in acute myeloid leukemia. Blood 1990;76:480-488
Web of Science | Medline34
Reiffers J ,Gaspard MH ,Maraninchi D , et al. Comparison of allogeneic or autologous bone marrow transplantation and chemotherapy in patients with acute myeloid leukaemia in first remission: a prospective controlled trial. Br J Haematol 1989;72:57-63
CrossRef | Web of Science | Medline35
Lowenberg B ,Verdonck LJ ,Dekker AW , et al. Autologous bone marrow transplantation in acute myeloid leukemia in first remission: results of a Dutch prospective study. J Clin Oncol 1990;8:287-294
Web of Science | Medline36
Schiller GJ ,Nimer SD ,Territo MC ,Ho WG ,Champlin RE ,Gajewski JL . Bone marrow transplantation versus high-dose cytarabine-based consolidation chemotherapy for acute myelogenous leukemia in first remission. J Clin Oncol 1992;10:41-46
Web of Science | Medline37
Cassileth PA ,Lynch E ,Hines JD , et al. Varying intensity of postremission therapy in acute myeloid leukemia. Blood 1992;79:1924-1930
Web of Science | Medline38
Zittoun R ,Liso V ,Mandelli F , et al. Intensive consolidation chemotherapy versus standard consolidation maintenance in acute myelogenous leukemia (AML) in first remission: an EORTC/GIMEMA phase III trial (AML8 B). Leukemia 1992;6:Suppl 2:76-77
Web of Science | Medline39
Mayer RJ ,Davis RB ,Schiffer CA , et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia. N Engl J Med 1994;331:896-903
Full Text | Web of Science | Medline40
Harousseau JL ,Pignon B ,Dufour P , et al. Autologous bone marrow transplantation vs intensive chemotherapy in first complete remission: interim results of GOELAM study in AML. Leukemia 1992;6:Suppl 2:120-123
Web of Science | Medline41
Harousseau JL ,Milpied N ,Briere J , et al. Double intensive consolidation chemotherapy in adult acute myeloid leukemia. J Clin Oncol 1991;9:1432-1437
Web of Science | Medline42
Clift RA ,Buckner CD ,Appelbaum FR , et al. Allogeneic marrow transplantation during untreated first relapse of acute myeloid leukemia. J Clin Oncol 1992;10:1723-1729
Web of Science | Medline43
Petersen FB ,Lynch MH ,Clift RA , et al. Autologous marrow transplantation for patients with acute myeloid leukemia in untreated first relapse or in second complete remission. J Clin Oncol 1993;11:1353-1360
Web of Science | Medline44
Fenaux P ,Le Deley MC ,Castaigne S , et al. Effect of all transretinoic acid in newly diagnosed acute promyelocytic leukemia: results of a multicenter randomized trial. Blood 1993;82:3241-3249
Web of Science | Medline
- Citing Articles (288)
Citing Articles
1
R Devillier, R Crocchiolo, L Castagna, S Fürst, J El Cheikh, C Faucher, T Prebet, A Etienne, C Chabannon, N Vey, B Esterni, D Blaise. (2012) The increase from 2.5 to 5 mg/kg of rabbit anti-thymocyte-globulin dose in reduced intensity conditioning reduces acute and chronic GVHD for patients with myeloid malignancies undergoing allo-SCT. Bone Marrow Transplantation
CrossRef2
Todd L. Rosenblat, Joseph G. Jurcic. (2011) Induction and Postremission Strategies in Acute Myeloid Leukemia: State of the Art and Future Directions. Hematology/Oncology Clinics of North America 25:6, 1189-1213
CrossRef3
John J. Schmidt, Jaehyun Jeong, Hyunjoon Kong. (2011) The Interplay Between Cell Adhesion Cues and Curvature of Cell Adherent Alginate Microgels in Multipotent Stem Cell Culture. Tissue Engineering Part A 17:21-22, 2687-2694
CrossRef4
Christian Wilhelm, Andreas Neubauer, Andreas Burchert. (2011) Poor-risk cytogenetics may be associated with inferior outcome after fludarabine, cytarabine, and amsacrine reduced intensity conditioning in patients with high-risk acute myeloid leukemia. Leukemia & Lymphoma 52:10, 2031-2035
CrossRef5
E. Vellenga, W. van Putten, G. J. Ossenkoppele, L. F. Verdonck, M. Theobald, J. J. Cornelissen, P. C. Huijgens, J. Maertens, A. Gratwohl, R. Schaafsma, U. Schanz, C. Graux, H. C. Schouten, A. Ferrant, M. Bargetzi, M. F. Fey, B. Lowenberg. (2011) Autologous peripheral blood stem cell transplantation for acute myeloid leukemia. Blood
CrossRef6
Christian Saure, Thomas Schroeder, Fabian Zohren, Anke Groten, Ingmar Bruns, Akos Czibere, Lars Galonska, Mustafa Kondakci, Christian Weigelt, Roland Fenk, Ulrich Germing, Rainer Haas, Guido Kobbe. (2011) Upfront Allogeneic Blood Stem Cell Transplantation for Patients with High-Risk Myelodysplastic Syndrome or Secondary Acute Myeloid Leukemia Using a FLAMSA-Based High-Dose Sequential Conditioning Regimen. Biology of Blood and Marrow Transplantation
CrossRef7
K Ishiyama, A Takami, Y Kanda, S Nakao, M Hidaka, T Maeda, T Naoe, S Taniguchi, K Kawa, T Nagamura, Y Atsuta, H Sakamaki. (2011) Allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia with t(6;9)(p23;q34) dramatically improves the patient prognosis: a matched-pair analysis. Leukemia
CrossRef8
Shui Cao, Yun-Liang Wang, Xiu-Bao Ren, Jin-Pu Yu, Bao-Zhu Ren, Xin-Wei Zhang, Wei-Hong Zhang, Ying Han. (2011) Efficacy of Large Doses of IL-2-Activated Human Leukocyte Antigen Haploidentical Peripheral Blood Stem Cells on Refractory Metastatic Renal Cell Carcinoma. Cancer Biotherapy & Radiopharmaceuticals 26:4, 503-510
CrossRef9
A. Perrot, I. Luquet, A. Pigneux, F. Mugneret, J. Delaunay, J.-L. Harousseau, C. Barin, J.-Y. Cahn, P. Guardiola, C. Himberlin, C. Recher, N. Vey, B. Lioure, M. Ojeda-Uribe, N. Fegueux, C. Berthou, E. Randriamalala, M. C. Bene, N. Ifrah, F. Witz, . (2011) Dismal prognostic value of monosomal karyotype in elderly patients with acute myeloid leukemia: a GOELAMS study of 186 patients with unfavorable cytogenetic abnormalities. Blood 118:3, 679-685
CrossRef10
M. Buyse, P. Squifflet, B. J. Lange, T. A. Alonzo, R. A. Larson, J. E. Kolitz, S. L. George, C. D. Bloomfield, S. Castaigne, S. Chevret, D. Blaise, D. Maraninchi, K. J. Lucchesi, T. Burzykowski. (2011) Individual patient data meta-analysis of randomized trials evaluating IL-2 monotherapy as remission maintenance therapy in acute myeloid leukemia. Blood 117:26, 7007-7013
CrossRef11
Nicolas Novitzky, Valda Thomas, Cecile du Toit, Andrew McDonald. (2011) Is There a Role for Autologous Stem Cell Transplantation for Patients with Acute Myelogenous Leukemia? A Retrospective Analysis. Biology of Blood and Marrow Transplantation 17:6, 875-884
CrossRef12
Steven E. McCormack, Qing Cao, Betul Oran, Daniel J. Weisdorf, Erica D. Warlick. (2011) Pre-transplant consolidation chemotherapy may not improve outcomes after reduced intensity conditioning hematopoietic stem cell transplantation for acute myeloid leukemia in first complete remission. Leukemia Research 35:6, 757-761
CrossRef13
Sherif S. Farag, Kati Maharry, Mei-Jie Zhang, Waleska S. Pérez, Stephen L. George, Krzysztof Mrózek, John DiPersio, Donald W. Bunjes, Guido Marcucci, Maria R. Baer, Mitchell Cairo, Edward Copelan, Corey S. Cutler, Luis Isola, Hillard M. Lazarus, Mark R. Litzow, David I. Marks, Olle Ringdén, David A. Rizzieri, Robert Soiffer, Richard A. Larson, Martin S. Tallman, Clara D. Bloomfield, Daniel J. Weisdorf. (2011) Comparison of Reduced-Intensity Hematopoietic Cell Transplantation with Chemotherapy in Patients Age 60-70 Years with Acute Myelogenous Leukemia in First Remission. Biology of Blood and Marrow Transplantation
CrossRef14
Melhem Solh, Todd E. DeFor, Daniel J. Weisdorf, Dan S. Kaufman. (2011) Extramedullary Relapse of Acute Myelogenous Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation: Better Prognosis Than Systemic Relapse. Biology of Blood and Marrow Transplantation
CrossRef15
H. F. Fernandez, Z. Sun, M. R. Litzow, S. M. Luger, E. M. Paietta, J. Racevskis, G. Dewald, R. P. Ketterling, J. M. Rowe, H. M. Lazarus, M. S. Tallman. (2011) Autologous transplantation gives encouraging results for young adults with favorable-risk acute myeloid leukemia, but is not improved with gemtuzumab ozogamicin. Blood 117:20, 5306-5313
CrossRef16
Jens Marcus Chemnitz, Marie Lilienfeld-Toal, Udo Holtick, Sebastian Theurich, Alexander Shimabukuro-Vornhagen, Anke Krause, Peter Brossart, Michael Hallek, Christof Scheid. (2011) Intermediate intensity conditioning regimen containing FLAMSA, treosulfan, cyclophosphamide, and ATG for allogeneic stem cell transplantation in elderly patients with relapsed or high-risk acute myeloid leukemia. Annals of Hematology
CrossRef17
M Hong, Q Wu, C Hu, J Fang, Y You, Z Zhong, P Zou, Y Hu, L Xia. (2011) Idarubicin-intensified BUCY2 regimens may lower relapse rate and improve survival in patients undergoing allo-SCT for high-risk hematological malignancies: a retrospective analysis. Bone Marrow Transplantation
CrossRef18
N S Majhail, R Bajorunaite, H M Lazarus, Z Wang, J P Klein, M J Zhang, J D Rizzo. (2011) High probability of long-term survival in 2-year survivors of autologous hematopoietic cell transplantation for AML in first or second CR. Bone Marrow Transplantation 46:3, 385-392
CrossRef19
S. Miyawaki, S. Ohtake, S. Fujisawa, H. Kiyoi, K. Shinagawa, N. Usui, T. Sakura, K. Miyamura, C. Nakaseko, Y. Miyazaki, A. Fujieda, T. Nagai, T. Yamane, M. Taniwaki, M. Takahashi, F. Yagasaki, Y. Kimura, N. Asou, H. Sakamaki, H. Handa, S. Honda, K. Ohnishi, T. Naoe, R. Ohno. (2011) A randomized comparison of 4 courses of standard-dose multiagent chemotherapy versus 3 courses of high-dose cytarabine alone in postremission therapy for acute myeloid leukemia in adults: the JALSG AML201 Study. Blood 117:8, 2366-2372
CrossRef20
I. Nivison-Smith, A. J. Dodds, H. Dunckley, D. D. F. Ma, J. J. Moore, J. M. Simpson, J. Szer, K. F. Bradstock. (2011) Increased activity and improved outcome in unrelated donor haemopoietic cell transplants for acute myeloid leukaemia in Australia, 1992-2005. Internal Medicine Journal 41:1a, 27-34
CrossRef21
Serena Meraviglia, Carmela La Mendola, Valentina Orlando, Francesco Scarpa, Giuseppe Cicero, Francesco Dieli. (2010) Vγ9Vδ2 T cells as a promising innovative tool for immunotherapy of hematologic malignancies. Oncology Reviews 4:4, 211-218
CrossRef22
N.-C. Gorin, M. Labopin, J. Reiffers, N. Milpied, D. Blaise, F. Witz, T. de Witte, G. Meloni, M. Attal, T. Bernal, V. Rocha, . (2010) Higher incidence of relapse in patients with acute myelocytic leukemia infused with higher doses of CD34+ cells from leukapheresis products autografted during the first remission. Blood 116:17, 3157-3162
CrossRef23
William Arcese, Francesco Buccisano, Raffaella Cerretti, Alessandra Picardi. (2010) Cord blood transplantation in adults with acute myeloid leukaemia. Best Practice & Research Clinical Haematology 23:2, 197-206
CrossRef24
Brian T. Hill, Edward A. Copelan. (2010) Acute Myeloid Leukemia: When to Transplant in First Complete Remission. Current Hematologic Malignancy Reports 5:2, 101-108
CrossRef25
R M Lemoli, A D'Addio, G Marotta, L Pezzullo, E Zuffa, M Montanari, A De Vivo, A Bonini, P Galieni, A M Carella, S Guidi, M Michieli, A Olivieri, A Bosi. (2010) BU/melphalan and auto-SCT in AML patients in first CR: a ‘Gruppo Italiano Trapianto di Midollo Osseo (GITMO)’ retrospective study. Bone Marrow Transplantation 45:4, 640-646
CrossRef26
Norbert Vey, Frank Giles. (2010) Laromustine (cloretazine). Expert Opinion on Pharmacotherapy 11:4, 657-667
CrossRef27
Y R Abou-Mourad, B C Lau, M J Barnett, D L Forrest, D E Hogge, S H Nantel, T J Nevill, J D Shepherd, C A Smith, K W Song, H J Sutherland, C L Toze, J C Lavoie. (2010) Long-term outcome after allo-SCT: close follow-up on a large cohort treated with myeloablative regimens. Bone Marrow Transplantation 45:2, 295-302
CrossRef28
Francesco Buccisano, Luca Maurillo, Alessandra Spagnoli, Maria Ilaria Del Principe, Eleonora Ceresoli, Francesco Lo Coco, William Arcese, Sergio Amadori, Adriano Venditti. (2009) Monitoring of minimal residual disease in acute myeloid leukemia. Current Opinion in Oncology 21:6, 582-588
CrossRef29
Hans-Jochem Kolb, Belinda Simoes, Christoph Schmid. (2009) Stem cell transplants for patients with relapsed/refractory leukaemia. Current Opinion in Hematology 16:6, 444-452
CrossRef30
Xavier Thomas, Emmanuel Raffoux, Mohamed Elhamri, Ida Lobe, Giovanna Cannas, Hervé Dombret. (2009) Clofarabine for the treatment of adult acute myeloid leukemia. Future Oncology 5:8, 1197-1210
CrossRef31
Andre S. Jung, Peter R. Holman, Januario E. Castro, Ewa K. Carrier, Asad Bashey, Thomas A. Lane, Connie L. Nelson, Minya Pu, Karen Messer, Sue M. Corringham, Edward D. Ball. (2009) Autologous Hematopoietic Stem Cell Transplantation as an Intensive Consolidation Therapy for Adult Patients in Remission from Acute Myelogenous Leukemia. Biology of Blood and Marrow Transplantation 15:10, 1306-1313
CrossRef32
Sebastian Giebel, Myriam Labopin, Jerzy Holowiecki, Boris Labar, Mieczyslaw Komarnicki, Vladimir Koza, Tamas Masszi, Martin Mistrik, Andrzej Lange, Andrzej Hellmann, Antonin Vitek, Joze Pretnar, Jiri Mayer, Piotr Rzepecki, Karel Indrak, Wieslaw Wiktor-Jedrzejczak, Jerzy Wojnar, Malgorzata Krawczyk-Kulis, Slawomira Kyrcz-Krzemien, Vanderson Rocha. (2009) Outcome of HLA-matched related allogeneic hematopoietic stem cell transplantation for patients with acute leukemia in first complete remission treated in Eastern European centers. Better results in recent years. Annals of Hematology 88:10, 1005-1013
CrossRef33
I. M. Borrello, H. I. Levitsky, W. Stock, D. Sher, L. Qin, D. J. DeAngelo, E. P. Alyea, R. M. Stone, L. E. Damon, C. A. Linker, D. J. Maslyar, K. M. Hege. (2009) Granulocyte-macrophage colony-stimulating factor (GM-CSF)-secreting cellular immunotherapy in combination with autologous stem cell transplantation (ASCT) as postremission therapy for acute myeloid leukemia (AML). Blood 114:9, 1736-1745
CrossRef34
Theodore C Bergstrom, Rodney J Garratt, Damien Sheehan-Connor. (2009) One Chance in a Million: Altruism and the Bone Marrow Registry. American Economic Review 99:4, 1309-1334
CrossRef35
Anders Wahlin, Rolf Billström, Ove Björ, Tomas Ahlgren, Michael Hedenus, Martin Höglund, Anders Lindmark, Berit Markevärn, Bo Nilsson, Bengt Sallerfors, Mats Brune. (2009) Results of risk-adapted therapy in acute myeloid leukaemia. A long-term population-based follow-up study. European Journal of Haematology 83:2, 99-107
CrossRef36
Keith Wheatley, Anthony H. Goldstone, Tim Littlewood, Anne Hunter, Alan K. Burnett. (2009) Randomized placebo-controlled trial of granulocyte colony stimulating factor (G-CSF) as supportive care after induction chemotherapy in adult patients with acute myeloid leukaemia: a study of the United Kingdom Medical Research Council Adult Leukaemia Working Party. British Journal of Haematology 146:1, 54-63
CrossRef37
Cortney V Jones, Edward A Copelan. (2009) Treatment of acute myeloid leukemia with hematopoietic stem cell transplantation. Future Oncology 5:4, 559-568
CrossRef38
S. Buchholz, A. Ganser. (2009) Hämatopoetische Stammzelltransplantation. Der Internist 50:5, 572-580
CrossRef39
J. Braess, K. Spiekermann, P. Staib, A. Gruneisen, B. Wormann, W.-D. Ludwig, H. Serve, A. Reichle, R. Peceny, D. Oruzio, C. Schmid, X. Schiel, M. Hentrich, C. Sauerland, M. Unterhalt, M. Fiegl, W. Kern, C. Buske, S. Bohlander, A. Heinecke, H. Baurmann, D. W. Beelen, W. E. Berdel, T. Buchner, W. Hiddemann. (2009) Dose-dense induction with sequential high-dose cytarabine and mitoxantone (S-HAM) and pegfilgrastim results in a high efficacy and a short duration of critical neutropenia in de novo acute myeloid leukemia: a pilot study of the AMLCG. Blood 113:17, 3903-3910
CrossRef40
A. R. Derolf, S. Y. Kristinsson, T. M.-L. Andersson, O. Landgren, P. W. Dickman, M. Bjorkholm. (2009) Improved patient survival for acute myeloid leukemia: a population-based study of 9729 patients diagnosed in Sweden between 1973 and 2005. Blood 113:16, 3666-3672
CrossRef41
M Kapp, S Stevanović, K Fick, S M Tan, J Loeffler, A Opitz, T Tonn, G Stuhler, H Einsele, G U Grigoleit. (2009) CD8+ T-cell responses to tumor-associated antigens correlate with superior relapse-free survival after allo-SCT. Bone Marrow Transplantation 43:5, 399-410
CrossRef42
R P Gale, M Eapen, B Logan, M-J Zhang, H M Lazarus. (2009) Are there roles for observational database studies and structured quantification of expert opinion to answer therapy controversies in transplants?. Bone Marrow Transplantation 43:6, 435-446
CrossRef43
Andrea Camera, Ciro R. Rinaldi, Salvatore Palmieri, Nicola Cantore, Giuseppina Mele, Vincenzo Mettivier, Eustachio Miraglia, Lucia Mastrullo, Francesco Grimaldi, Luigia Luciano, Anna Guerriero, Bruno Rotoli, Felicetto Ferrara. (2009) Sequential continuous infusion of fludarabine and cytarabine associated with liposomal daunorubicin (DaunoXome®) (FLAD) in primary refractory or relapsed adult acute myeloid leukemia patients. Annals of Hematology 88:2, 151-158
CrossRef44
Tadeusz Robak, Agnieszka Wierzbowska. (2009) Current and emerging therapies for acute myeloid leukemia. Clinical Therapeutics 31, 2349-2370
CrossRef45
Tara Seshadri, Armand Keating. (2009) Is There a Role for Autotransplants in AML in First Remission?. Biology of Blood and Marrow Transplantation 15:1, 17-20
CrossRef46
Mehdi Hamadani, Farrukh T. Awan. (2009) Remission induction, consolidation and novel agents in development for adults with acute myeloid leukaemia. Hematological Oncologyn/a-n/a
CrossRef47
Anna Candoni, Giovanni Martinelli, Eleonora Toffoletti, Alexia Chiarvesio, Mario Tiribelli, Michele Malagola, Pier Paolo Piccaluga, Angela Michelutti, Erica Simeone, Daniela Damiani, Domenico Russo, Renato Fanin. (2008) Gemtuzumab-ozogamicin in combination with fludarabine, cytarabine, idarubicin (FLAI-GO) as induction therapy in CD33-positive AML patients younger than 65 years. Leukemia Research 32:12, 1800-1808
CrossRef48
Matt Kalaycio, Anjali Advani, Brad Pohlman, Mikkael Sekeres, Barbara Tripp, Lisa Rybicki, Ronald Sobecks. (2008) Timed sequential induction chemotherapy and risk-adapted postremission therapy for acute myelogenous leukemia. American Journal of Hematology 83:11, 831-834
CrossRef49
Hagop Kantarjian, Susan O'Brien, Jorge Cortes, William Wierda, Stefan Faderl, Guillermo Garcia-Manero, Jean-Pierre Issa, Elihu Estey, Michael Keating, Emil J. Freireich. (2008) Therapeutic advances in leukemia and myelodysplastic syndrome over the past 40 years. Cancer 113:S7, 1933-1952
CrossRef50
P. Kumpers, C. Koenecke, H. Hecker, J. Hellpap, R. Horn, W. Verhagen, S. Buchholz, B. Hertenstein, J. Krauter, M. Eder, S. David, G. Gohring, H. Haller, A. Ganser. (2008) Angiopoietin-2 predicts disease-free survival after allogeneic stem cell transplantation in patients with high-risk myeloid malignancies. Blood 112:5, 2139-2148
CrossRef51
Iztok Hozo, Michael J. Schell, Benjamin Djulbegovic. (2008) Decision-Making When Data and Inferences Are Not Conclusive: Risk-Benefit and Acceptable Regret Approach. Seminars in Hematology 45:3, 150-159
CrossRef52
Nicolas Novitzky, Valda Thomas, Cecile du Toit, Andrew Mcdonald. (2008) In Stem Cell Transplantation by Limiting the Morbidity of Graft-versus-Host Disease Tolerance to Myeloablative Conditioning is Improved. Biology of Blood and Marrow Transplantation 14:6, 709-718
CrossRef53
Takehiko Mori, Yoshinobu Aisa, Reiko Watanabe, Rie Yamazaki, Jun Kato, Takayuki Shimizu, Naoyuki Shigematsu, Atsushi Kubo, Tomonaru Yajima, Toshifumi Hibi, Yasuo Ikeda, Shinichiro Okamoto. (2008) Long-Term Follow-up of Allogeneic Hematopoietic Stem Cell Transplantation for De Novo Acute Myelogenous Leukemia with a Conditioning Regimen of Total Body Irradiation and Granulocyte Colony-Stimulating Factor-Combined High-Dose Cytarabine. Biology of Blood and Marrow Transplantation 14:6, 651-657
CrossRef54
Mehdi Hamadani, Farrukh T. Awan, Edward A. Copelan. (2008) Hematopoietic Stem Cell Transplantation in Adults with Acute Myeloid Leukemia. Biology of Blood and Marrow Transplantation 14:5, 556-567
CrossRef55
Anthony R Mato, Alicia Morgans, Selina M Luger. (2008) Novel strategies for relapsed and refractory acute myeloid leukemia. Current Opinion in Hematology 15:2, 108-114
CrossRef56
J Sierra, R Martino, B Sánchez, J L Piñana, D Valcárcel, S Brunet. (2008) Hematopoietic transplantation from adult unrelated donors as treatment for acute myeloid leukemia. Bone Marrow Transplantation 41:5, 425-437
CrossRef57
Richard F. Schlenk, Marcelo C. Pasquini, Waleska S. Pérez, Mei-Jie Zhang, Jürgen Krauter, Joseph H. Antin, Asad Bashey, Brian J. Bolwell, Thomas Büchner, Jean-Yves Cahn, Mitchell S. Cairo, Edward A. Copelan, Corey S. Cutler, Hartmut Döhner, Robert Peter Gale, Osman Ilhan, Hillard M. Lazarus, Jane L. Liesveld, Mark R. Litzow, David I. Marks, Richard T. Maziarz, Philip L. McCarthy, Stephen D. Nimer, Jorge Sierra, Martin S. Tallman, Daniel J. Weisdorf, Mary M. Horowitz, Arnold Ganser. (2008) HLA-Identical Sibling Allogeneic Transplants versus Chemotherapy in Acute Myelogenous Leukemia with t(8;21) in First Complete Remission: Collaborative Study between the German AML Intergroup and CIBMTR. Biology of Blood and Marrow Transplantation 14:2, 187-196
CrossRef58
Denise M. Oliansky, Frederick Appelbaum, Peter A. Cassileth, Armand Keating, Jamie Kerr, Yago Nieto, Susan Stewart, Richard M. Stone, Martin S. Tallman, Philip L. McCarthy, Theresa Hahn. (2008) The Role of Cytotoxic Therapy with Hematopoietic Stem Cell Transplantation in the Therapy of Acute Myelogenous Leukemia in Adults: An Evidence-Based Review. Biology of Blood and Marrow Transplantation 14:2, 137-180
CrossRef59
James M. Coghill, Michael J. Carlson, Tim P. Moran, Jonathan S. Serody. (2008) The biology and therapeutic potential of natural regulatory T-cells in the bone marrow transplant setting. Leukemia & Lymphoma 49:10, 1860-1869
CrossRef60
Katsuji Shinagawa. (2008) Okayama Igakkai Zasshi (Journal of Okayama Medical Association) 120:2, 175-184
CrossRef61
Ken Bradstock. (2008) Can the influence of karyotype in acute myeloid leukemia be overcome by high-dose chemotherapy?. Leukemia & Lymphoma 49:12, 2227-2228
CrossRef62
Marco Montillo, Alessandra Tedeschi, Livio Pagano, Adriano Venditti, Felicetto Ferrara, Piero Fabris, Bruno Martino, Maurizio Musso, Gennaro De Rosa, Giorgina Specchia, Michele Monaco, Giovanni Sparaventi, Antonio Spadea, Angelo Palmas, Wilma Deplano, Annunziata Manna, Lorella Melillo, Eustachio Miraglia, Salvatore Mirto, Franco Mandelli for the Gimema Group. (2008) Feasibility of peripheral blood stem cell rescue as intensification in elderly patients with acute myelocytic leukaemia: a pilot study from the Gimema Group. British Journal of Haematology 111:1, 334
CrossRef63
Christine Fernandez, Christine Fernandez, Véronique Leblond, Johnny Moretto. 2008. Traitement des leucémies. , 655-670.
CrossRef64
Stephen H. Petersdorf, Cathryn Rankin, David R. Head, Howard R. Terebelo, Cheryl L. Willman, Stanley P. Balcerzak, Anand B. Karnad, Shaker R. Dakhil, Frederick R. Appelbaum. (2007) Phase II evaluation of an intensified induction therapy with standard daunomycin and cytarabine followed by high dose cytarabine for adults with previously untreated acute myeloid leukemia: A southwest oncology group study (SWOG-9500). American Journal of Hematology 82:12, 1056-1062
CrossRef65
Farhad Ravandi, Alan K. Burnett, Edward D. Agura, Hagop M. Kantarjian. (2007) Progress in the treatment of acute myeloid leukemia. Cancer 110:9, 1900-1910
CrossRef66
John G. Gribben. 2007. Management of Haematological Malignancies. .
CrossRef67
Dimitri A. Breems, Bob Löwenberg. (2007) Acute Myeloid Leukemia and the Position of Autologous Stem Cell Transplantation. Seminars in Hematology 44:4, 259-266
CrossRef68
T L Kiss, W Sabry, H M Lazarus, J H Lipton. (2007) Blood and marrow transplantation in elderly acute myeloid leukaemia patients – older certainly is not better. Bone Marrow Transplantation 40:5, 405-416
CrossRef69
D Vicente, T Lamparelli, F Gualandi, D Occhini, A M Raiola, A Ibatici, M T Van Lint, M Gobbi, M Miglino, M Clavio, M Risso, F Frassoni, A Bacigalupo. (2007) Improved outcome in young adults with de novo acute myeloid leukemia in first remission, undergoing an allogeneic bone marrow transplant. Bone Marrow Transplantation 40:4, 349-354
CrossRef70
Chih-Cheng Chen, Jyh-Pyng Gau, Yuan-Bin Yu, Chang-Hsien Lu, Kuan-Der Lee, Jie-Yu You. (2007) Prognosis and treatment outcome in patients with acute myeloid Leukemia with t(8;21)(q22;q22). Advances in Therapy 24:4, 907-920
CrossRef71
Pirjo Koistinen, Riikka Räty, Maija Itälä, Esa Jantunen, Elli Koivunen, Tapio Nousiainen, Tarja-Terttu Pelliniemi, Kari Remes, Tapani Ruutu, Eeva-Riitta Savolainen, Timo Siitonen, Raija Silvennoinen, Liisa Volin, Erkki Elonen, . (2007) Long-term outcome of intensive chemotherapy for adults with de novo acute myeloid leukaemia (AML): the nationwide AML-92 study by the Finnish Leukaemia Group. European Journal of Haematology 78:6, 477-486
CrossRef72
Aristeidis Chaidos, Ed Kanfer, Jane F. Apperley. (2007) Risk assessment in haemotopoietic stem cell transplantation: Disease and disease stage. Best Practice & Research Clinical Haematology 20:2, 125-154
CrossRef73
Felicetto Ferrara, Assunta Viola, Carolina Copia, Claudio Falco, Rossella D'Elia, Francesco Paolo Tambaro, Pasqualino Correale, Maria Rosaria D'Amico, Laura Vicari, Salvatore Palmieri. (2007) Age has no influence on mobilization of peripheral blood stem cells in acute myeloid leukemia. Hematological Oncology 25:2, 84-89
CrossRef74
Xiu-Bao Ren, Jin-Pu Yu, Shui Cao, Bao-Zhu Ren, Hui Li, Hong Liu, Wei-Ping Min, Xi-Shan Hao. (2007) Antitumor Effect of Large Doses IL-2-Activated HLA Haploidentical Peripheral Blood Stem Cells on Refractory Metastatic Solid Tumor Treatment. Cancer Biotherapy & Radiopharmaceuticals 22:2, 223-234
CrossRef75
R M Sobecks, E J Ball, J P Maciejewski, L A Rybicki, S Brown, M Kalaycio, B Pohlman, S Andresen, K S Theil, R Dean, B J Bolwell. (2007) Survival of AML patients receiving HLA-matched sibling donor allogeneic bone marrow transplantation correlates with HLA-Cw ligand groups for killer immunoglobulin-like receptors. Bone Marrow Transplantation 39:7, 417-424
CrossRef76
Charles Linker. (2007) The role of autologous transplantation for acute myeloid leukemia in first and second remission. Best Practice & Research Clinical Haematology 20:1, 77-84
CrossRef77
Tsila Zuckerman, Jacob M Rowe. (2007) Alternative donor transplantation in acute myeloid leukemia: which source and when?. Current Opinion in Hematology 14:2, 152-161
CrossRef78
Frédéric Baron, Rainer Storb. (2007) Hematopoietic cell transplantation after reduced-intensity conditioning for older adults with acute myeloid leukemia in complete remission. Current Opinion in Hematology 14:2, 145-151
CrossRef79
Jeong Hwa Do, Seung Hwan Oh, Eun Ju Song, Joo Seop Chung, Chi Duk Kang, Eun Yup Lee. (2007) Treatment Outcome of Multidrug Resistance Related mRNA Expression and c-Jun-N-Terminal Kinase Activity in Patients with Acute Myeloid Leukemia. The Korean Journal of Laboratory Medicine 27:4, 229
CrossRef80
Lois J. Ayash, Voravit Ratanatharathorn, Thomas Braun, Samuel M. Silver, Christopher M. Reynolds, Joseph P. Uberti. (2007) Unrelated donor bone marrow transplantation using a chemotherapy-only preparative regimen for adults with high-risk acute myelogenous leukemia. American Journal of Hematology 82:1, 6-14
CrossRef81
Seung Tai Kim, Chul Won Jung, Jeeyun Lee, Jung Mi Kwon, Sung Young Oh, Byeong-Bae Park, Hyo Rak Lee, Hyun Jung Kim, Kihyun Kim, Won Seog Kim, Jin Seok Ahn, Won Ki Kang, Keunchil Park. (2007) Postremission therapy for acute myeloid leukemia in the first remission. Leukemia & Lymphoma 48:5, 937-943
CrossRef82
A-L Herr, M Labopin, D Blaise, N Milpied, M Potter, M Michallet, W Heit, F Ferrara, J Esteve, W Arcese, G Ehninger, J M Rowe, G Kobbe, A Rosselet, D Bunjes, B Rio, M Brune, A Nagler, N C Gorin, F Frassoni, V Rocha. (2007) HLA-identical sibling allogeneic peripheral blood stem cell transplantation with reduced intensity conditioning compared to autologous peripheral blood stem cell transplantation for elderly patients with de novo acute myeloid leukemia. Leukemia 21:1, 129-135
CrossRef83
Assunta Viola, Claudio Falco, Rossella D'Elia, Maria R. D'Amico, Laura Vicari, Francesco P. Tambaro, Pasqualino Correale, Daniela Laudati, Salvatore Palmieri, Felicetto Ferrara. (2007) An antecedent diagnosis of refractory anemia with excess blasts has no influence on mobilization of peripheral blood stem cells and hematopoietic recovery after autologous stem cell transplantation in acute myeloid leukemia. European Journal of Haematology 78:1, 41-47
CrossRef84
Tai Ju Hwang. (2007) Hematopoietic stem cell transplantation : overview for general pediatrician. Korean Journal of Pediatrics 50:7, 613
CrossRef85
Roberto Ria, Anna Maria Scarponi, Franca Falzetti, Stelvio Ballanti, Mauro Di Ianni, Paolo Sportoletti, Michele Cimminiello, Cristiana Gasbarrino, Benedetta Pallone, Angelo Vacca, Franco Dammacco, Elmo Mannarino, Antonio Tabilio. (2007) Loss of bone mineral density and secondary hyperparathyroidism are complications of autologous stem cell transplantation. Leukemia & Lymphoma 48:5, 923-930
CrossRef86
J. F. de Vries, L. J. Wammes, I. Jedema, L. van Dreunen, B. A. Nijmeijer, M. H. M. Heemskerk, R. Willemze, J. H. F. Falkenburg, R. M. Y. Barge. (2007) Involvement of caspase-8 in chemotherapy-induced apoptosis of patient derived leukemia cell lines independent of the death receptor pathway and downstream from mitochondria. Apoptosis 12:1, 181-193
CrossRef87
Dietger Niederwieser, Thoralf Lange, Michael Cross, Nadesda Basara, Haifa Al-Ali. (2006) Reduced intensity conditioning (RIC) haematopoietic cell transplants in elderly patients with AML. Best Practice & Research Clinical Haematology 19:4, 825-838
CrossRef88
, D. W. Milligan, D. Grimwade, J. O. Cullis, L. Bond, D. Swirsky, C. Craddock, J. Kell, J. Homewood, K. Campbell, S. McGinley, K. Wheatley, G. Jackson. (2006) Guidelines on the management of acute myeloid leukaemia in adults. British Journal of Haematology 135:4, 450-474
CrossRef89
U Jehn, S Suciu, X Thomas, F Lefrère, P Muus, Z Berneman, J-P Marie, F Adamo, G Fillet, F Nobile, F Ricciuti, G Leone, V Rizzoli, M Montanaro, F Beeldens, P Fazi, F Mandelli, R Willemze, T de Witte, S Amadori. (2006) Non-infusional vs intravenous consolidation chemotherapy in elderly patients with acute myeloid leukemia: final results of the EORTC-GIMEMA AML-13 randomized phase III trial. Leukemia 20:10, 1723-1730
CrossRef90
F Buccisano, L Maurillo, V Gattei, G Del Poeta, M I Del Principe, M C Cox, P Panetta, M Irno Consalvo, C Mazzone, B Neri, L Ottaviani, D Fraboni, A Tamburini, F Lo-Coco, S Amadori, A Venditti. (2006) The kinetics of reduction of minimal residual disease impacts on duration of response and survival of patients with acute myeloid leukemia. Leukemia 20:10, 1783-1789
CrossRef91
Leona A. Holmberg, F. Marc Stewart. (2006) Revisiting the role of dose intensity in hematological malignancies. Experimental Hematology 34:7, 811-825
CrossRef92
Lisa Y. Law, Sandra J. Horning, Ruby M. Wong, Laura J. Johnston, Ginna G. Laport, Robert Lowsky, Judith A. Shizuru, Karl G. Blume, Robert S. Negrin, Keith E. Stockerl-Goldstein. (2006) High-Dose Carmustine, Etoposide, and Cyclophosphamide Followed by Allogeneic Hematopoietic Cell Transplantation for Non-Hodgkin Lymphoma. Biology of Blood and Marrow Transplantation 12:7, 703-711
CrossRef93
M. CHANDY. (2006) An approach to the management of leukemia in the developing world. Clinical and Laboratory Haematology 28:3, 147-153
CrossRef94
Kenneth Bradstock. (2006) Chemotherapy for patients with acute myeloid leukemia in first remission. Current Hematologic Malignancy Reports 1:2, 108-113
CrossRef95
Frederick R. Appelbaum, S. Frieda Pearce. (2006) Hematopoietic cell transplantation in first complete remission versus early relapse. Best Practice & Research Clinical Haematology 19:2, 333-339
CrossRef96
Jacob M. Rowe. (2006) Is there a role for consolidation therapy pre-transplantation?. Best Practice & Research Clinical Haematology 19:2, 301-310
CrossRef97
R. Marks, J. Finke. (2006) Die Bedeutung der Stammzelltherapie in der Hämatologie und Onkologie. Der Internist 47:5, 467-478
CrossRef98
Javier Bolaños-Meade, Eric Hartley, Richard J. Jones. (2006) Long-Term Follow-up of Allogeneic Marrow Transplantation for Acute Myelogenous Leukemia after Treatment with Busulfan and Cyclophosphamide. Biology of Blood and Marrow Transplantation 12:3, 366-367
CrossRef99
Gordon Cook, Richard E. Clark, Charles Crawley, Stephen Mackinnon, Nigel Russell, Kirsty Thomson, Rachel M. Pearce, Keiren Towlson, David I. Marks. (2006) The Outcome of Sibling and Unrelated Donor Allogeneic Stem Cell Transplantation in Adult Patients with Acute Myeloid Leukemia in First Remission Who Were Initially Refractory to First Induction Chemotherapy. Biology of Blood and Marrow Transplantation 12:3, 293-300
CrossRef100
G Heil, D Hoelzer, M A Sanz, K Lechner, L Noens, J Szer, A Ganser, J Matcham, J Renwick. (2006) Long-term survival data from a phase 3 study of Filgrastim as an adjunct to chemotherapy in adults with de novo acute myeloid leukemia. Leukemia 20:3, 404-409
CrossRef101
K. NOMURA, K. KAWASUGI, T. MORIMOTO. (2006) Cost-effectiveness analysis of antifungal treatment for patients on chemotherapy. European Journal of Cancer Care 15:1, 44-50
CrossRef102
Hillard M. Lazarus, Waleska S. Perez, John P. Klein, Craig Kollman, B. Bate-Boyle, Christopher N. Bredeson, Robert Peter Gale, Robert B. Geller, Armand Keating, Mark R. Litzow, David I. Marks, Carole B. Miller, J. Douglas Rizzo, Thomas R. Spitzer, Daniel J. Weisdorf, Mei-Jie Zhang, Mary M. Horowitz. (2006) Autotransplantation versus HLA-matched unrelated donor transplantation for acute myeloid leukaemia: a retrospective analysis from the Center for International Blood and Marrow Transplant Research. British Journal of Haematology 132:6, 755-769
CrossRef103
Norbert Vey, Frank Giles. (2006) Cloretazine for the treatment of acute myeloid leukemia. Expert Review of Anticancer Therapy 6:3, 321-328
CrossRef104
E. J. Jabbour, E. Estey, H. M. Kantarjian. (2006) Adult Acute Myeloid Leukemia. Mayo Clinic Proceedings 81:2, 247-260
CrossRef105
Felicetto Ferrara, Salvatore Palmieri, Maria Celentano, Mariacarla De Simone, Filiberto Pollio, Maria Rosaria D'Amico, Carolina Copia, Giuseppina Mele. (2006) Feasibility of autologous peripheral blood stem cell transplantation in elderly patients with acute myeloid leukemia. Leukemia & Lymphoma 47:8, 1593-1598
CrossRef106
G. Visani, A. Olivieri, M. Malagola, M. Brunori, P. P. Piccaluga, D. Capelli, G. Pomponio, G. Martinelli, A. Isidori, G. Sparaventi, P. Leoni. (2006) Consolidation therapy for adult acute myeloid leukemia: A systematic analysis according to evidence based medicine. Leukemia & Lymphoma 47:6, 1091-1102
CrossRef107
Evandro M. Fagundes, Vanderson Rocha, Ana Beatriz F. Glória, Nelma Cristina D. Clementino, José S. Quintão, João Paulo O. Guimarães, Ênio Roberto P. Pedroso, Marcos B. Viana. (2006) De novo acute myeloid leukemia in adults younger than 60 years of age: Socioeconomic aspects and treatment results in a Brazilian university center. Leukemia & Lymphoma 47:8, 1557-1564
CrossRef108
Thomas Büchner, Wolfgang E. Berdel, Bernhard Wörmann, Claudia Schoch, Torsten Haferlach, Susanne Schnittger, Wolfgang Kern, Carlo Aul, Eva Lengfelder, Andrea Schumacher, Albrecht Reichle, Peter Staib, Leopold Balleisen, Hartmut Eimermacher, Andreas Grüneisen, Herbert Rasche, Maria Cristina Sauerland, Achim Heinecke, Rolf M. Mesters, Hubert L. Serve, Joachim Kienast, Wolfgang Hiddemann. (2005) Treatment of older patients with AML. Critical Reviews in Oncology/Hematology 56:2, 247-259
CrossRef109
Dietger Niederwieser, Chiara Gentilini, Ute Hegenbart, Thoralf Lange, Cornelia Becker, Song-Yau Wang, Kristina Bartsch, Wolfram Pönisch, Martin Raida, Haifa Al-Ali. (2005) Allogeneic hematopoietic cell transplantation (HCT) following reduced-intensity conditioning in patients with acute leukemias. Critical Reviews in Oncology/Hematology 56:2, 275-281
CrossRef110
Weitao Huang, Weihong Tan, Qiu Zhong, Paul Schwarzenberger. (2005) Development of a gene therapy based bone marrow purging system for leukemias. Cancer Gene Therapy 12:11, 873-883
CrossRef111
Didier P. Blaise, Jean Michel Boiron, Catherine Faucher, Mohamad Mohty, Jacques-Olivier Bay, Valerie-Jeanne Bardoux, Virginie Perreau, Diane Coso, Arnaud Pigneux, Norbert Vey. (2005) Reduced intensity conditioning prior to allogeneic stem cell transplantation for patients with acute myeloblastic leukemia as a first-line treatment. Cancer 104:9, 1931-1938
CrossRef112
Wolfgang Kern, Claudia Schoch, Torsten Haferlach, Susanne Schnittger. (2005) Monitoring of minimal residual disease in acute myeloid leukemia. Critical Reviews in Oncology/Hematology 56:2, 283-309
CrossRef113
Domenico Russo, Michele Malagola, Antonio Vivo, Mauro Fiacchini, Giovanni Martinelli, Pier P. Piccaluga, Daniela Damiani, Anna Candoni, Angela Michielutti, Maurizio Castelli, Nicoletta Testoni, Emanuela Ottaviani, Michela Rondoni, Giancarla Pricolo, Patrizio Mazza, Eliana Zuffa, Alfonso Zaccaria, Donatella Raspadori, Monica Bocchia, Francesco Lauria, Alessandro Bonini, Paolo Avanzini, Luigi Gugliotta, Giuseppe Visani, Renato Fanin, Michele Baccarani. (2005) Multicentre phase III trial on fludarabine, cytarabine (Ara-C), and idarubicin versus idarubicin, Ara-C and etoposide for induction treatment of younger, newly diagnosed acute myeloid leukaemia patients. British Journal of Haematology 131:2, 172-179
CrossRef114
Wolfgang Kern, Susanne Schnittger. (2005) Monitoring of minimal residual disease in acute myeloid leukemia Monitorisierung minimaler Resterkrankung bei akuter myeloischer Leukämie. LaboratoriumsMedizin 29:5, 343-367
CrossRef115
Alan Burnett. (2005) The treatment of AML: Current status and novel approaches. Hematology 10:4, 50-53
CrossRef116
Dimitri A. Breems, Bob Lowenberg. (2005) Autologous stem cell transplantation in the treatment of adults with acute myeloid leukaemia. British Journal of Haematology 130:6, 825-833
CrossRef117
K W Song, J Lipton. (2005) Is it appropriate to offer allogeneic hematopoietic stem cell transplantation to patients with primary refractory acute myeloid leukemia?. Bone Marrow Transplantation 36:3, 183-191
CrossRef118
D Osborne, L Frost, K Tobal, J A Liu Yin. (2005) Elevated levels of WT1 transcripts in bone marrow harvests are associated with a high relapse risk in patients autografted for acute myeloid leukaemia. Bone Marrow Transplantation 36:1, 67-70
CrossRef119
A Shimoni, A Nagler. (2005) Allogeneic hematopoietic stem-cell transplantation in patients with acute myeloid leukemia in first complete remission: new answers for an old question. Leukemia 19:6, 891-893
CrossRef120
Alexandra Böhm, Maria Piribauer, Friedrich Wimazal, Klaus Geissler, Heinz Gisslinger, Paul Knöbl, Ulrich Jäger, Christa Fonatsch, Paul A. Kyrle, Peter Valent, Klaus Lechner, Wolfgang R. Sperr. (2005) High dose intermittent ARA-C (HiDAC) for consolidation of patients with de novo AML: a single center experience. Leukemia Research 29:6, 609-615
CrossRef121
M Mohty, H de Lavallade, P Ladaique, C Faucher, N Vey, D Coso, A-M Stoppa, J-A Gastaut, D Blaise. (2005) The role of reduced intensity conditioning allogeneic stem cell transplantation in patients with acute myeloid leukemia: a donor vs no donor comparison. Leukemia 19:6, 916-920
CrossRef122
Eric Jourdan, Francoise Rigal-Huguet, Gerald Marit, Norbert Vey, Nicole Dastugue, Nathalie Fegueux, Lysiane Molina, Jean-Albert Gastaut, Laurence Legros, Hacene Zerazhi, Sylvie Cailleres, Frederic Bauduer, Dominique Bordessoule, Michel Attal, Didier Blaise, Arnaud Pigneux, . (2005) One versus two high-dose cytarabine-based consolidation before autologous stem cell transplantation for young acute myeloblastic leukaemia patients in first complete remission. British Journal of Haematology 129:3, 403-410
CrossRef123
Masamitsu Yanada, Keitaro Matsuo, Nobuhiko Emi, Tomoki Naoe. (2005) Efficacy of allogeneic hematopoietic stem cell transplantation depends on cytogenetic risk for acute myeloid leukemia in first disease remission. Cancer 103:8, 1652-1658
CrossRef124
Jeeyun Lee, Mark H. Lee, Keon Woo Park, Jung Hoon Kang, Do Hyung Im, Kihyun Kim, Se-Hoon Lee, Won Seog Kim, Jinny Park, Chul Won Jung, Keunchil Parka. (2005) Influential Factors for the Collection of Peripheral Blood Stem Cells and Engraftment in Acute Myeloid Leukemia Patients in First Complete Remission. International Journal of Hematology 81:3, 258-263
CrossRef125
Kevin W Song, Peter N Mollee, Donna E Hogge, Vikas Gupta, Michael J Barnett, Donna L Forrest, Julye C Lavoie, Thomas J Nevill, Stephen H Nantel, John D Shepherd, Clay A Smith, Heather J Sutherland, Cynthia L Toze, Michael Crump, Armand Keating. (2005) Predictive value of karyotype on outcome of autotransplants for acute myeloid leukemia in second remission. Leukemia & Lymphoma 46:4, 525-531
CrossRef126
Lauri Burroughs, Rainer Storb. (2005) Low-intensity allogeneic hematopoietic stem cell transplantation for myeloid malignancies: separating graft-versus-leukemia effects from graft-versus-host disease. Current Opinion in Hematology 12:1, 45-54
CrossRef127
Felicetto Ferrara, Salvatore Palmieri, Mariacarla De Simone, Marco Sagristani, Assunta Viola, Barbara Pocali, Alfredo Fasanaro, Giuseppina Mele. (2005) High-dose idarubicin and busulphan as conditioning to autologous stem cell transplantation in adult patients with acute myeloid leukaemia. British Journal of Haematology 128:2, 234-241
CrossRef128
K. N. Leung, N. K. Mak, M. C. Fung. (2005) Cytokines in the Differentiation Therapy of Leukemia: From Laboratory Investigations to Clinical Applications. Critical Reviews in Clinical Laboratory Sciences 42:5-6, 473-514
CrossRef129
X Thomas, QH Le, S de Botton, E Raffoux, Y Chelghoum, C Pautas, F Dreyfus, N Dhedin, A Vekhoff, J Troncy, A Pigneux, T de Revel, O Reman, P Travade, A Thiebaut, A Guerci, M Elhamri, P Fenaux, H Dombret, M Michallet. (2005) Autologous or allogeneic stem cell transplantation as post-remission therapy in refractory or relapsed acute myeloid leukemia after highly intensive chemotherapy. Leukemia & Lymphoma 46:7, 1007-1016
CrossRef130
Dimitri A. Breems, Marc A. Boogaerts, Adriaan W. Dekker, Wim L. J. Van Putten, Pieter Sonneveld, Peter C. Huijgens, Johannes Van der Lelie, Edo Vellenga, Alois Gratwohl, Gregor E. G. Verhoef, Leo F. Verdonck, Bob Löwenberg. (2005) Autologous bone marrow transplantation as consolidation therapy in the treatment of adult patients under 60 years with acute myeloid leukaemia in first complete remission: a prospective randomized Dutch-Belgian Haemato-Oncology Co-operative Group (HOVON) and Swiss Group for Clinical Cancer Research (SAKK) trial. British Journal of Haematology 128:1, 59-65
CrossRef131
Peter Cassileth, Sandra Lee, Mark Litzow, Kenneth Miller, Edward Stadtmauer, Martin Tallman, Hillard Lazarus, John Bennett, Elisabeth Paietta, Gordon Dewald, Jacob Rowe. (2005) Intensified induction chemotherapy in adult acute myeloid leukemia followed by high-dose chemotherapy and autologous peripheral blood stem cell transplantation: an eastern cooperative oncology group trial (E4995). Leukemia & Lymphoma 46:1, 55-61
CrossRef132
Massimo Berger, Ivana Ferrero, Elena Vassallo, Luca Gastaldo, Francesca Carraro, Eleonora Biasin, Enrico Madon, Franca Fagioli. (2005) STEM CELL TRANSPLANTATION AS CONSOLIDATION THERAPY FOR CHILDREN IN FIRST-REMISSION AML. Pediatric Hematology-Oncology 22:7, 597-608
CrossRef133
Jérôme Cornillon, Abir Fawaz, Stéphane Depil, Françoise Dufosse, Alain Duhamel, Francis Bauters, Pierre Fenaux, Jean-Pierre Jouet, Ibrahim Yakoub-Agha. (2005) Outcome of patients less than 55 years of age with high-risk acute leukemia who did not have an human leukocyte antigen-identical related donor: a long-term study of 97 consecutive patients. Leukemia & Lymphoma 46:6, 841-849
CrossRef134
Marco Mielcarek, Rainer Storb. (2005) Graft-vs-host disease after non-myeloablative hematopoietic cell transplantation. Leukemia & Lymphoma 46:9, 1251-1260
CrossRef135
D. Hernández Maraver, J. Gracia Colldeforns, T. Cobo Rodríguez, F. Hernández Navarro. (2004) Leucemias agudas en el adulto. Medicine - Programa de Formación Médica Continuada Acreditado 9:21, 1314-1324
CrossRef136
N. Novitzky, V. Thomas, L. Abrahams, C. du Toit, A. McDonald. (2004) Increasing dose intensity of anthracycline antibiotics improves outcome in patients with acute myelogenous leukemia. American Journal of Hematology 76:4, 319-329
CrossRef137
Thomas R. Chauncey. (2004) Autologous bone marrow transplantation improves disease free survival but not overall survival in people with acute myeloid leukaemia. Cancer Treatment Reviews 30:5, 483-487
CrossRef138
J TRELEAVEN. (2004) Acute leukaemia. Medicine 32:6, 65-69
CrossRef139
Hiroyasu Ogawa, Kazuhiro Ikegame, Manabu Kawakami, Satoshi Takahashi, Hisashi Sakamaki, Takahiro Karasuno, Hiroshi Sao, Yoshihisa Kodera, Noriyuki Hirabayashi, Shinichiro Okamoto, Mine Harada, Koji Iwato, Atsuo Maruta, Mitsune Tanimoto, Keisei Kawa. (2004) Impact of Cytogenetics on Outcome of Stem Cell Transplantation for Acute Myeloid Leukemia in First Remission: A Large-Scale Retrospective Analysis of Data from the Japan Society for Hematopoietic Cell Transplantation. International Journal of Hematology 79:5, 495-500
CrossRef140
Matthew Smith, Michael Barnett, Renato Bassan, Gemma Gatta, Carlo Tondini, Wolfgang Kern. (2004) Adult acute myeloid leukaemia. Critical Reviews in Oncology/Hematology 50:3, 197-222
CrossRef141
Itai Levi, Itamar Grotto, Ronit Yerushalmi, Isaac Ben-Bassat, Ofer Shpilberg. (2004) Meta-analysis of autologous bone marrow transplantation versus chemotherapy in adult patients with acute myeloid leukemia in first remission. Leukemia Research 28:6, 605-612
CrossRef142
C Hallemeier, M Girgis, W Blum, R Brown, H Khoury, L.T Goodnough, R Vij, S Devine, M Wehde, S Postma, H.-S Lin, J Dipersio, D Adkins. (2004) Outcomes of adults with acute myelogenous leukemia in remission given 550 cGy of single-exposure total body irradiation, cyclophosphamide, and unrelated donor bone marrow transplants. Biology of Blood and Marrow Transplantation 10:5, 310-319
CrossRef143
Edmund K Waller. (2004) Cellular immunotherapy and cancer. Seminars in Oncology 31, 87-90
CrossRef144
Elliott F Winton, Amelia A Langston. (2004) Update in acute leukemia 2003: A risk adapted approach to acute myeloblastic leukemia in adults. Seminars in Oncology 31, 80-86
CrossRef145
Michelle M Bishop, John R Wingard. (2004) Thriving after hematopoietic stem cell transplant: a focus on positive changes in quality of life. Expert Review of Pharmacoeconomics & Outcomes Research 4:1, 111-123
CrossRef146
P. C. Nathan, L. Sung, M. Crump, J. Beyene. (2004) Consolidation Therapy With Autologous Bone Marrow Transplantation in Adults With Acute Myeloid Leukemia: A Meta-analysis. JNCI Journal of the National Cancer Institute 96:1, 38-45
CrossRef147
Werner Rabitsch, Wolfgang R Sperr, Klaus Lechner, Andreas Chott, Erika Prinz, Peter Valent, Peter Kalhs. (2004) Bone Marrow Microvessel Density and it's Prognostic Significance in AML. Leukemia & Lymphoma 45:7, 1369-1373
CrossRef148
Michael Boyiadzis, Steven Pavletic. (2004) Haematopoietic stem cell transplantation: indications, clinical developments and future directions. Expert Opinion on Pharmacotherapy 5:1, 97-108
CrossRef149
Anthony H Goldstone, Panagiotis D Kottaridis. (2003) The Allogeneic Effect in Non-Hodgkin's Lymphoma. Leukemia & Lymphoma 44:S3, S91-S97
CrossRef150
Soheil Meshinchi, Wendy M Leisenring, Paul A Carpenter, Ann E Woolfrey, Eric L Sievers, Jerald P Radich, Jean E Sanders. (2003) Survival after second hematopoietic stem cell transplantation for recurrent pediatric acute myeloid leukemia. Biology of Blood and Marrow Transplantation 9:11, 706-713
CrossRef151
Wolfgang Kern, Susanne Schnittger. (2003) Monitoring of acute myeloid leukemia by flow cytometry. Current Oncology Reports 5:5, 405-412
CrossRef152
Alberto Redaelli, Jennifer M Lee, Jennifer M Stephens, Chris L Pashos. (2003) Epidemiology and clinical burden of acute myeloid leukemia. Expert Review of Anticancer Therapy 3:5, 695-710
CrossRef153
J.H.Frederik Falkenburg, Lisette van de Corput, Erik W.A Marijt, Roel Willemze. (2003) Minor histocompatibility antigens in human stem cell transplantation. Experimental Hematology 31:9, 743-751
CrossRef154
Marco Mielcarek, Rainer Storb. (2003) Non-myeloablative hematopoietic cell transplantation as immunotherapy for hematologic malignancies. Cancer Treatment Reviews 29:4, 283-290
CrossRef155
Hatice Duzkale, Lance C Pagliaro, Michael G Rosenblum, Ali Varan, Baoshun Liu, James Reuben, William G Wierda, Martin Korbling, John D McMannis, Armand B Glassman, David A Scheinberg, Emil J Freireich. (2003) Bone marrow purging studies in acute myelogenous leukemia using the recombinant anti-CD33 immunotoxin HuM195/rGel. Biology of Blood and Marrow Transplantation 9:6, 364-372
CrossRef156
Apostolia-Maria Tsimberidou, Niki Stavroyianni, Nora Viniou, Maria Papaioannou, Maria Tiniakou, Theodoros Marinakis, Anastasia Skandali, Ioanna Sakellari, Xenophon Yataganas, . (2003) Comparison of allogeneic stem cell transplantation, high-dose cytarabine, and autologous peripheral stem cell transplantation as postremission treatment in patients with de novo acute myelogenous leukemia. Cancer 97:7, 1721-1731
CrossRef157
Javier Bolaños-Meade, Judith E Karp, Chuanfa Guo, Clarence B Sarkodee-Adoo, Aaron P Rapoport, Michael L Tidwell, Laxmi N Buddharaju, T.Timothy Chen. (2003) Timed sequential therapy of acute myelogenous leukemia in adults: a phase II study of retinoids in combination with the sequential administration of cytosine arabinoside, idarubicin and etoposide. Leukemia Research 27:4, 313-321
CrossRef158
Lillian Sung, Rena Buckstein, John J. Doyle, Michael Crump, Allan S. Detsky. (2003) Treatment options for patients with acute myeloid leukemia with a matched sibling donor. Cancer 97:3, 592-600
CrossRef159
Frederick R. Appelbaum. (2003) The Current Status of Hematopoietic Cell Transplantation. Annual Review of Medicine 54:1, 491-512
CrossRef160
J.F.A. Noronha, C.A. De Souza, A.C. Vigorito, F.J.P. Aranha, R. Zulli, E.C.M. Miranda, H.Z.W. Grotto. (2003) Immature reticulocytes as an early predictor of engraftment in autologous and allogeneic bone marrow transplantation. Clinical and Laboratory Haematology 25:1, 47-54
CrossRef161
Lyle C. Feinstein, Brenda M. Sandmaier, Ute Hegenbart, Peter A. McSweeney, David G. Maloney, Theodore A. Gooley, Michael B. Maris, Thomas R. Chauncey, Benedetto Bruno, Frederick R. Appelbaum, Dietger W. Niederwieser, Rainer F. Storb. (2003) Non-myeloablative allografting from human leucocyte antigen-identical sibling donors for treatment of acute myeloid leukaemia in first complete remission. British Journal of Haematology 120:2, 281-288
CrossRef162
Yaddanapudi Ravindranath. (2003) Recent advances in pediatric acute lymphoblastic and myeloid leukemia. Current Opinion in Oncology 15:1, 23-35
CrossRef163
Jennifer J. Clark, Franklin O. Smith, Robert J. Arceci. (2003) Update in childhood acute myeloid leukemia: recent developments in the molecular basis of disease and novel therapies. Current Opinion in Hematology 10:1, 31-39
CrossRef164
Noriko Usui, Nobuaki Dobashi, Osamu Asai, Shingo Yano, Yuichi Yahagi, Takeshi Saito, Yuko Yamaguchi, Kinuyo Kasama, Yutaka Okawa, Naohiro Sekiguchi, Yutaka Takei, Katsuki Sugiyama, Yoji Ogasawara, Hiroko Ohtsubo, Ken Kaito, Masayuki Kobayashi. (2002) Intensified Daunorubicin in Induction Therapy and Autologous Peripheral Blood Stem Cell Transplantation in Postremission Therapy (Double-7 Protocol) for Adult Acute Myeloid Leukemia. International Journal of Hematology 76:5, 436-445
CrossRef165
Thomas Büchner, Hartmut Döhner, Gerhard Ehninger, Arnold Ganser, Jörg Hasford. (2002) Up-front randomization and common standard arm: a proposal for comparing AML treatment strategies between different studies. Leukemia Research 26:12, 1073-1075
CrossRef166
J. H. F. Falkenburg, W. A. F. Marijt, M. H. M. Heemskerk, R. Willemze. (2002) Minor histocompatibility antigens as targets of graft-versus-leukemia reactions. Current Opinion in Hematology 9:6, 497-502
CrossRef167
Felicetto Ferrara, Adriano Venditti, Angelo Michele Carellajr, Nicola Cantore, Francesco Buccisano, Anna Tamburini, Salvatore Palmieri, Giuseppina Mele, Mario Annunziata, Michele Mario Greco, Sergio Amadori. (2002) Autologous stem-cell transplantation for patients with acute myeloid leukemia aged over 60 yr. European Journal of Haematology 69:4, 200-204
CrossRef168
Jonathan Soboloff, Yicheng Zhang, Mark Minden, Stuart A Berger. (2002) Sensitivity of myeloid leukemia cells to calcium influx blockade. Experimental Hematology 30:10, 1219-1226
CrossRef169
Jochen Greiner, Mark Ringhoffer, Masanori Taniguchi, Anita Schmitt, Dieter Kirchner, Gertraud Krähn, Volker Heilmann, Jürgen Gschwend, Lothar Bergmann, Hartmut Döhner, Michael Schmitt. (2002) Receptor for hyaluronan acid–mediated motility (RHAMM) is a new immunogenic leukemia-associated antigen in acute and chronic myeloid leukemia. Experimental Hematology 30:9, 1029-1035
CrossRef170
Keith Wheatley. (2002) Current controversies: which patients with acute myeloid leukaemia should receive a bone marrow transplantation? - A statistician's view. British Journal of Haematology 118:2, 351-356
CrossRef171
Alan K. Burnett. (2002) Current Controversies: Which Patients With Acute Myeloid Leukaemia Should Receive A Bone Marrow Transplantation? - An Adult Treater's View. British Journal of Haematology 118:2, 357-364
CrossRef172
Torsten Haferlach, Claudia Schoch, Susanne Schnittger, Wolfgang Kern, Helmut Loffler, Wolfgang Hiddemann. (2002) Distinct genetic patterns can be identified in acute monoblastic and acute monocytic leukaemia (FAB AML M5a and M5b): a study of 124 patients. British Journal of Haematology 118:2, 426-431
CrossRef173
Ursula Creutzig, Dirk Reinhardt. (2002) current controversies: which patients with acute myeloid leukaemia should receive a bone marrow transplantation? - A European view. British Journal of Haematology 118:2, 365-377
CrossRef174
Alan K. Burnett, Keith Wheatley, Anthony H. Goldstone, Richard F. Stevens, Ian M. Hann, John H. K. Rees, Georgina Harrison, . (2002) The value of allogeneic bone marrow transplant in patients with acute myeloid leukaemia at differing risk of relapse: results of the UK MRC AML 10 trial. British Journal of Haematology 118:2, 385-400
CrossRef175
Richard M Stone. (2002) Treatment of acute myeloid leukemia: State-of-the-art and future directions. Seminars in Hematology 39:3, 4-10
CrossRef176
Edward A Stadtmauer. (2002) Histamine dihydrochloride and interleukin-2 in the treatment of acute myeloid leukemia. Seminars in Oncology 29:3, 47-51
CrossRef177
Pieter K. Wierenga, Rita Setroikromo, Gera Kamps, Harm H. Kampinga, Edo Vellenga. (2002) Peripheral Blood Stem Cells Differ from Bone Marrow Stem Cells in Cell Cycle Status, Repopulating Potential, and Sensitivity Toward Hyperthermic Purging in Mice Mobilized with Cyclophosphamide and Granulocyte Colony-Stimulating Factor. Journal of Hematotherapy <html_ent glyph="@amp;" ascii="&"/> Stem Cell Research 11:3, 523-532
CrossRef178
Hildegard T. Greinix, David Nachbaur, Otto Krieger, Margit Eibl, Paul Knöbl, Peter Kalhs, Dieter Lutz, Werner Linkesch, Dietger Niederwieser, Wolfgang Hinterberger, Klaus Lechner, Agathe Rosenmayr, Beate Gritsch. (2002) Factors affecting long-term outcome after allogeneic haematopoietic stem cell transplantation for acute myelogenous leukaemia: a retrospective study of 172 adult patients reported to the Austrian Stem Cell Transplantation Registry. British Journal of Haematology 117:4, 914-923
CrossRef179
F. Baron, Y. Beguin. (2002) Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation. Journal of Hematotherapy <html_ent glyph="@amp;" ascii="&"/> Stem Cell Research 11:2, 243-263
CrossRef180
Norbert-Claude Gorin. (2002) Autologous stem cell transplantation for adult acute leukemia. Current Opinion in Oncology 14:2, 152-159
CrossRef181
Alan K. Burnett. (2002) ACUTE MYELOID LEUKEMIA: TREATMENTOF ADULTS UNDER 60 YEARS. Reviews in Clinical and Experimental Hematology 6:1, 26-45
CrossRef182
Øystein Bruserud, Nils Glenjen, Bjørn Tore Gjertsen, Lars Herfindal, Stein Ove Døskeland. (2002) Use of marine toxins in combination with cytotoxic drugs for induction of apoptosis in acute myelogenous leukaemia cells. Expert Opinion on Biological Therapy 2:2, 197-210
CrossRef183
Tadeusz Robak, Agata Wrzesień-Kuś. (2002) The Search for Optimal Treatment in Relapsed and Refractory Acute Myeloid Leukemia. Leukemia & Lymphoma 43:2, 281-291
CrossRef184
Adrian Newland. (2002) Progress in the treatment of acute myeloid leukaemia in adults. International Journal of Hematology 76:S1, 253-258
CrossRef185
Lance H. Leopold, Roel Willemze. (2002) The Treatment of Acute Myeloid Leukemia in First Relapse: A Comprehensive Review of the Literature. Leukemia & Lymphoma 43:9, 1715-1727
CrossRef186
David I. Marks. (2001) Allogeneic transplantation for leukaemia using unrelated donors. Best Practice & Research Clinical Haematology 14:4, 793-805
CrossRef187
Sergio Rutella, Luca Pierelli, Giuseppina Bonanno, Andrea Mariotti, Simona Sica, Federica Sorà, Patrizia Chiusolo, Giovanni Scambia, Carlo Rumi, Giuseppe Leone. (2001) Immune reconstitution after autologous peripheral blood progenitor cell transplantation. Experimental Hematology 29:12, 1503-1516
CrossRef188
Lyle Feinstein, Rainer Storb. (2001) Reducing transplant toxicity. Current Opinion in Hematology 8:6, 342-348
CrossRef189
Øystein Wendelboe, Øystein Bruserud. (2001) Biological treatment in acute myelogenous leukaemia: how should T-cell targeting immunotherapy be combined with intensive chemotherapy?. Expert Opinion on Biological Therapy 1:6, 1005-1016
CrossRef190
Rolf E. Brouwer, Juliette Hoefnagel, Boudewijn Borger van der Burg, Inge Jedema, Koos H. Zwinderman, Ingrid C. W. Starrenburg, Hanneke C. Kluin-Nelemans, Renee M. Y. Barge, Roel Willemze, J. H. Frederik Falkenburg. (2001) Expression of co-stimulatory and adhesion molecules and chemokine or apoptosis receptors on acute myeloid leukaemia: high CD40 and CD11a expression correlates with poor prognosis. British Journal of Haematology 115:2, 298-308
CrossRef191
Susanne W Reif, Dagmar Wiesner, Thomas Duell, Johann Mittermueller, Helga M Schmetzer. (2001) Not the presence but the amount of clonal DNA detectable in remission of acute myeloid leukemia is predictive for relapse. European Journal of Haematology 67:4, 207-220
CrossRef192
A Pinto, V Zagonel, F Ferrara. (2001) Acute myeloid leukemia in the elderly: biology and therapeutic strategies. Critical Reviews in Oncology/Hematology 39:3, 275-287
CrossRef193
M. Macheta, J. A. Liu Yin. (2001) Recent advances in the treatment of AML. Hematological Oncology 19:3, 107-118
CrossRef194
Elihu H. Estey. (2001) Therapeutic options for acute myelogenous leukemia. Cancer 92:5, 1059-1073
CrossRef195
W.A.F. Marijt, J.H.F. Falkenburg. (2001) Specific T Cell Therapy in Leukemia. Journal of Hematotherapy <html_ent glyph="@amp;" ascii="&"/> Stem Cell Research 10:4, 493-500
CrossRef196
Richard M Stone. (2001) Postremission therapy in adults with acute myeloid leukemia. Seminars in Hematology 38, 17-23
CrossRef197
Alan K Burnett. (2001) Introduction: Modern management of acute myeloid leukemia. Seminars in Hematology 38, 1-2
CrossRef198
LYLE FEINSTEIN, BRENDA SANDMAIER, DAVID MALONEY, PETER A. McSWEENEY, MICHAEL MARIS, CHRISTOPHER FLOWERS, JERRY RADICH, MARIE-TÉRÈSE LITTLE, RICHARD A. NASH, THOMAS CHAUNCEY, ANN WOOLFREY, GEORGE GEORGES, HANS-PETER KIEM, JAN M. ZAUCHA, KARL G. BLUME, JUDITH SHIZURU, DIETGER NIEDERWIESER, RAINER STORB. (2001) Nonmyeloablative Hematopoietic Cell Transplantation. Annals of the New York Academy of Sciences 938:1, 328-339
CrossRef199
Corey Cutler, Joseph H. Antin. (2001) Peripheral Blood Stem Cells for Allogeneic Transplantation: A Review. Stem Cells 19:2, 108-117
CrossRef200
Bob Löwenberg. (2001) Prognostic factors in acute myeloid leukaemia. Best Practice & Research Clinical Haematology 14:1, 65-75
CrossRef201
Hui-Chi Hsu, Jyh-Pyng Gau, Jacqueline Ming Liu, Wing-Keung Chau, Chao-Hung Ho. (2001) Intensive postremission chemotherapy in Taiwanese adults with acute myelogenous leukemia. Advances in Therapy 18:2, 67-74
CrossRef202
Lyle Feinstein, Rainer Storb. (2001) Nonmyeloablative hematopoietic cell transplantation. Current Opinion in Oncology 13:2, 95-100
CrossRef203
C.A. Uyl-de Groot, J. Gelderblom-den Hartog, P.C. Huijgens, R. Willemze, B.M. van Ineveld. (2001) Costs of Diagnosis, Treatment, and Follow Up of Patients with Acute Myeloid Leukemia in the Netherlands. Journal of Hematotherapy <html_ent glyph="@amp;" ascii="&"/> Stem Cell Research 10:1, 187-192
CrossRef204
Domenico Russo, Giancarla Pricolo, Mariagrazia Michieli, Angela Michelutti, Donatella Raspadori, Antonella Bertone, Luciana Marin, Ivana Pierri, Alessandro Bucalossi, Eliana Zuffa, Antonio De Vivo, Patrizio Mazza, Marco Gobbi, Francesco Lauria, Alfonso Zaccaria, Michele Baccarani. (2001) Fludarabine, Arabinosyl Cytosine and Idarubicin (FLAI) for Remission Induction in Poor-Risk Acute Myeloid Leukemia. Leukemia & Lymphoma 40:3-4, 335-343
CrossRef205
Oystein Bruserud, Bjorn Tore Gjertsen, Hilde Loland von Volkman. (2000) In Vitro Culture of Human Acute Myelogenous Leukemia (AML) Cells in Serum-Free Media: Studies of Native AML Blasts and AML Cell Lines. Journal of Hematotherapy <html_ent glyph="@amp;" ascii="&"/> Stem Cell Research 9:6, 923-932
CrossRef206
Esteban Abella, Yaddanapudi Ravindranath. (2000) Therapy for childhood acute myeloid leukemia: Role of allogeneic bone marrow transplantation. Current Oncology Reports 2:6, 529-538
CrossRef207
Alan K. Burnett, Jonathan Kell, Clare Rowntree. (2000) Acute myeloid leukemia: therapeutic indications. Current Opinion in Hematology 7:6, 333-338
CrossRef208
Øystein Bruserud, Elling Ulvestad. (2000) Acute Myelogenous Leukemia Blasts as Accessory Cells during in Vitro T Lymphocyte Activation. Cellular Immunology 206:1, 36-50
CrossRef209
E.S. Sandler, R. Hagg, M.J. Coppes, M.M. Mustafa, A. Gamis, N. Kamani, D. Wall. (2000) Hematopoietic stem cell transplantation (HSCT) with a conditioning regimen of busulfan, cyclophosphamide, and etoposide for children with acute myelogenous leukemia (AML): A phase I study of the pediatric blood and marrow transplant consortium. Medical and Pediatric Oncology 35:4, 403-409
CrossRef210
Nabil Saba, Rick Abraham, Armand Keating. (2000) Overview of autologous stem cell transplantation. Critical Reviews in Oncology/Hematology 36:1, 27-48
CrossRef211
Marco Montillo, Alessandra Tedeschi, Livio Pagano, Adriano Venditti, Felicetto Ferrara, Piero Fabris, Bruno Martino, Maurizio Musso, Gennaro De Rosa, Giorgina Specchia, Michele Monaco, Giovanni Sparaventi, Antonio Spadea, Angelo Palmas, Wilma Deplano, Annunziata Manna, Lorella Melillo, Eustachio Miraglia, Salvatore Mirto, Franco Mandelli for the Gimema Group. (2000) Feasibility of peripheral blood stem cell rescue as intensification in elderly patients with acute myelocytic leukaemia: a pilot study from the Gimema Group. British Journal of Haematology 111:1, 334-337
CrossRef212
N. C. Gorin,, M. Labopin, P. Pichard, J. Sierra, D. Fiere, B. Rio, G. Meloni, M. A. Sanz,, A. Iriondo,, L. Fouillard, F. Frassoni, . (2000) Feasibility and recent improvement of autologous stem cell transplantation for acute myelocytic leukaemia in patients over 60 years of age: importance of the source of stem cells. British Journal of Haematology 110:4, 887-893
CrossRef213
Jean-Yves Cahn, Myriam Labopin, Jorge Sierra, Didier Blaise, Josy Reiffers, Augustin Ferrant, Lothar Bergmann, Giuseppe Visani, Jan Cornelissen, Theo De Witte, Alberto Bosi, Francesco Frassoni, Norbert-Claude Gorin, . (2000) No impact of high-dose cytarabine on the outcome of patients transplanted for acute myeloblastic leukaemia in first remission. British Journal of Haematology 110:2, 308-314
CrossRef214
Oystein Bruserud, Brynjar Foss, Jenny Foss Abrahamsen, Bjorn Tore Gjertsen, Peter Ernst. (2000) Autologous Stem Cell Transplantation As Post-Remission Therapy in Adult Acute Myelogenous Leukemia: Does Platelet Contamination of Peripheral Blood Mobilized Stem Cell Grafts Influence the Risk of Leukemia Relapse?. Journal of Hematotherapy <html_ent glyph="@amp;" ascii="&"/> Stem Cell Research 9:4, 433-443
CrossRef215
Vincent Lévy, Zora Marjanovic, Anne Vekhoff, Ramdam Belhocine, Jean Pierre Marie, Alain Delmer, Florence Ajchenbaum-Cymbalista, Robert Zittoun, Bernard Rio. (2000) Relapse after autologous hematopoietic stem cell transplantation in acute myeloid leukemia, a single center experience over 13 years. American Journal of Hematology 64:3, 232-233
CrossRef216
Vassiliki Danilatou, Evagelia Lydaki, Helen Dimitriou, Theodore Papazoglou, Maria Kalmanti. (2000) Bone marrow purging by photodynamic treatment in children with acute leukemia. Leukemia Research 24:5, 427-435
CrossRef217
Francesco Frassoni, Myriam Labopin, Ray Powles, Jean-Yves Mary, William Arcese, Andrea Bacigalupo, Donald Bunjes, Eliane Gluckman, Tapani Ruutu, Ulrich W Schaefer, Jorge Sierra, Jean Paul Vernant, Roel Willemze, Theo de Witte, Norbert Claude Gorin Transplantation. (2000) Effect of centre on outcome of bone-marrow transplantation for acute myeloid leukaemia. The Lancet 355:9213, 1393-1398
CrossRef218
Alan K Burnett, Jonathan Kell. (2000) High dose cytarabine or transplantation for consolidation of younger patients with acute myeloid leukemia. Current Opinion in Oncology 12:2, 110-115
CrossRef219
Larry D. Cripe, Stuart Hinton. (2000) Acute myeloid leukemia in adults. Current Treatment Options in Oncology 1:1, 9-17
CrossRef220
Norbert-Claude Gorin, Myriam Labopin, Jean-Philippe Laporte, Luc Douay, Manuel Lopez, Sylvie Lesage, Loı̈c Fouillard, Françoise Isnard, Jean-Pierre Jouet, Nassima Bellal, Christine Perot, Jacqueline Van Den Akker, Francis Bauters, Albert Najman. (1999) Importance of marrow dose on posttransplant outcome in acute leukemia. Experimental Hematology 27:12, 1822-1830
CrossRef221
Norbert Ifrah, Francis Witz, Jean-Pierre Jouet, Sylvie Fran
ois, Thierry Lamy, Claude Linassier, Bernard Pignon, Christian Berthou, Denis Guyotat, Jean-Yves Cahn, Jean-Luc Harousseau, . (1999) Intensive short term therapy with granulocyte-macrophage-colony stimulating factor support, similar to therapy for acute myeloblastic leukemia, does not improve overall results for adults with acute lymphoblastic leukemia. Cancer 86:8, 1496-1505
CrossRef222
Maggie Watson, Keith Wheatley, Georgina A. Harrison, Robert Zittoun, Richard G. Gray, Alan H. Goldstone, Alan K. Burnett. (1999) Severe adverse impact on sexual functioning and fertility of bone marrow transplantation, either allogeneic or autologous, compared with consolidation chemotherapy alone. Cancer 86:7, 1231-1239
CrossRef223
Brad Spellberg, Gary J. Schiller. (1999) AUTOLOGOUS BONE MARROW TRANSPLANTATION IN ACUTE LEUKEMIA. Hematology/Oncology Clinics of North America 13:5, 919-938
CrossRef224
M. Hokland, H. Jørgensen, Mette Skov Holm, Bengt Simonsson, Bo Nilsson, Mats Bengtsson, P. Hokland. (1999) Natural effector cells in patients with acute myeloid leukemia treated with the immunomodulator Linomide after autologous bone marrow transplantation. European Journal of Haematology 63:4, 251-258
CrossRef225
C. S. Chim, R. Liang, Y. L. Kwong, A. K. W. Lie, D. Todd, T. K. Chan. (1999) Treatment of de novo acute myeloid leukaemia in Hong Kong: a twenty-year experience (1975 to 1996). Australian and New Zealand Journal of Medicine 29:5, 726-730
CrossRef226
Lowenberg, Bob, Downing, James R., Burnett, Alan, . (1999) Acute Myeloid Leukemia. New England Journal of Medicine 341:14, 1051-1062
Full Text227
John R. Wingard, Jan S. Moreb, Rebecca I. Gaa. (1999) High-Dose Chemotherapy with Autologous Stem Cell Rescue as a Treatment Modality for Breast Cancer. The Breast Journal 5:5, 308-318
CrossRef228
Robert Peter Gale, Rolla Edward Park, Robert W. Dubois, Geoffrey P. Herzig, William G. Hocking, Mary M. Horowitz, Armand Keating, Sanford Kempin, Charles A. Linker, Charles A. Schiffer, Peter H. Wiernik, Daniel J. Weisdorf, Kanti R. Rai. (1999) Delphi-panel analysis of appropriateness of high-dose therapy and bone marrow transplants in adults with acute myelogenous leukemia in 1st remission. Leukemia Research 23:8, 709-718
CrossRef229
Andreas Engert, Andreas Josting, Marcel Reiser, Dietmar Söhngen, Volker Diehl. (1999) Aktueller Stellenwert der Hochdosistherapie in der Hämatologie und internistischen Onkologie. Medizinische Klinik 94:8, 431-442
CrossRef230
Socié, Gérard, Stone, Judith Veum, Wingard, John R., Weisdorf, Daniel, Henslee-Downey, P. Jean, Bredeson, Christopher, Cahn, Jean-Yves, Passweg, Jakob R., Rowlings, Philip A., Schouten, Harry C., Kolb, Hans-Jochem, Bender-Götze, Christine, Camitta, Bruce M., Godder, Kamar, Horowitz, Mary M., Wayne, Alan S., Klein, John P., . (1999) Long-Term Survival and Late Deaths after Allogeneic Bone Marrow Transplantation. New England Journal of Medicine 341:1, 14-21
Full Text231
Roberto Latagliata, Maria Concetta Petti, Franco Mandelli. (1999) Acute myeloid leukemia in the elderly: ‘per aspera ad astra’?. Leukemia Research 23:7, 603-613
CrossRef232
Alan K. Burnett. (1999) Tailoring the treatment of acute myeloid leukemia. Current Opinion in Hematology 6:4, 247
CrossRef233
Per Kragh Andersen, Mary M. Horowitz, John P. Klein, Gerard Socie, Judith Veum Stone, Mei-Jie Zhang. (1999) Modelling covariate adjusted mortality relative to a standard population. Statistics in Medicine 18:12, 1529-1540
CrossRef234
(1999) Treatment of Acute Myeloid Leukemia. New England Journal of Medicine 340:18, 1436-1439
Full Text235
Giovanni Del Poeta, Adriano Venditti, Roberto Stasi, Germano Aronica, Maria Christina Cox, Francesco Buccisano, Anna Tamburini, Antonio Bruno, Luca Maurillo, Alessandra Battaglia, Giovanna Suppo, Anna Maria Epiceno, Beatrice Del Moro, Mario Masi, Sergio Amadori, Giuseppe Papa. (1999) P-glycoprotein and terminal transferase expression identify prognostic subsets within cytogenetic risk classes in acute myeloid leukemia. Leukemia Research 23:5, 451-465
CrossRef236
S. Frostad, Ø. Bruserud. (1999) In vitro effects of insulin-like growth factor-1 (IGF-1) on proliferation and constitutive cytokine secretion by acute myelogenous leukemia blasts. European Journal of Haematology 62:3, 191-198
CrossRef237
U. CREUTZIG, M. ZIMMERMANN, J. RITTER, G. HENZE, N. GRAF, H. LOFFLER, G. SCHELLONG. (1999) Definition of a standard-risk group in children with AML. British Journal of Haematology 104:3, 630-639
CrossRef238
Nicolas Novitzky, Valda Thomas, Geoffrey Hale, Herman Waldmann. (1999) EX VIVO DEPLETION OF T CELLS FROM BONE MARROW GRAFTS WITH CAMPATH-1 IN ACUTE LEUKEMIA. Transplantation 67:4, 620-626
CrossRef239
Robert Zittoun, Sophie Achard, Martine Ruszniewski. (1999) Assessment of quality of life during intensive chemotherapy or bone marrow transplantation. Psycho-Oncology 8:1, 64-73
CrossRef240
Alan K. Burnett. (1999) Tailoring the treatment of acute myeloid leukemia. Current Opinion in Oncology 11:1, 14
CrossRef241
Burnett, Alan K., . (1998) Transplantation in First Remission of Acute Myeloid Leukemia. New England Journal of Medicine 339:23, 1698-1700
Full Text242
Cassileth, Peter A., Harrington, David P., Appelbaum, Frederick R., Lazarus, Hillard M., Rowe, Jacob M., Paietta, Elisabeth, Willman, Cheryl, Hurd, David D., Bennett, John M., Blume, Karl G., Head, David R., Wiernik, Peter H., . (1998) Chemotherapy Compared with Autologous or Allogeneic Bone Marrow Transplantation in the Management of Acute Myeloid Leukemia in First Remission. New England Journal of Medicine 339:23, 1649-1656
Full Text243
Eric Archimbaud, Xavier Thomas. (1998) Thrombopoietic factors potentially useful in the treatment of acute leukemia. Leukemia Research 22:12, 1155-1164
CrossRef244
Didier Blaise, Dominique Maraninchi. (1998) Interleukin 2 in the treatment of acute leukemia. Leukemia Research 22:12, 1165-1170
CrossRef245
Peter Jacobs. (1998) Myelodysplasia and the leukemias. Current Problems in Cancer 22:6, 384-464
CrossRef246
Yao, Bouchet, Harnois, Giarratana, Laporte, Gorin, Opez, Douay. (1998) Quantitative and qualitative alterations of long-term culture-initiating cells in patients with acute leukaemia in complete remission. British Journal of Haematology 103:1, 124-128
CrossRef247
Meral Beksaç, Önder Arslan, Haluk Koç, Hamdi Akan, Osman Ilhan, Mutlu Arat, Muhit Özcan, Günhan Gürman, Nahide Konuk, Akin Uysal. (1998) Randomised unicenter trial for comparison of three regimens inde novo adult acute nonlymphoblastic leukaemia. Medical Oncology 15:3, 183-190
CrossRef248
SUSAN KEATING, THEO DE WITTE, STEFAN SUCIU, ROEL WILLEMZE, MARCEL HAYAT, BORIS LABAR, LUIGI RESEGOTTI, PIERLUIGI ROSSI FERRINI, FRANCESCO CARONIA, MURIELLE DARDENNE, GABRIEL SOLBU, MARIA CONCETTA PETTI, MARIA LUCE VEGNA, FRANCO MANDELLI, ROBERT A. ZITTOUN, . (1998) The influence of HLA-matched sibling donor availability on treatment outcome for patients with AML: an analysis of the AML 8A study of the EORTC Leukaemia Cooperative Group and GIMEMA. British Journal of Haematology 102:5, 1344-1353
CrossRef249
Kiyoyuki Ogata, Emi An, Keiko Kamikubo, Norio Yokose, Hideto Tamura, Takashi Yamada, Seiji Gomi, Kazuo Dan, Takeo Nomura. (1998) Repeated Cycles of G‐CSF‐Combined Postremission Chemotherapy for Acute Myeloid Leukemia in a First Complete Remission: A Pilot Study. Stem Cells 16:4, 280-287
CrossRef250
Klaus Geissler, Eva Kabrna, Susanna Stengg, Ilse Schwarzinger, Paul KNÖbl, Peter Valent, Sabine Eichinger, Alan Barge, Klaus Lechner. (1998) Recombinant human megakaryocyte growth and development factor increases levels of circulating haemopoietic progenitor cells post chemotherapy in patients with acute myeloid leukaemia. British Journal of Haematology 102:2, 535-543
CrossRef251
Straetmans, Herman, Van Bockstaele, Michaux, Hagemeijer, Ferrant. (1998) Haemopoietic defect and decreased expansion potential of bone marrow autografts from patients with acute myeloid leukaemia in first remission. British Journal of Haematology 101:3, 571-581
CrossRef252
D. M. Thomas, J. F. Seymour, J. Szer, A. P. Grigg, R. L. Basser, M. D. Green, R. M. Fox. (1998) Progress in management of acute myeloid leukaemia (AML) in Australia since 1980: a single institution retrospective study. Australian and New Zealand Journal of Medicine 28:2, 190-196
CrossRef253
Alan K Burnett, Anthony H Goldstone, Richard MF Stevens, Ian M Hann, John KH Rees, Richard G Gray, Keith Wheatley. (1998) Randomised comparison of addition of autologous bone-marrow transplantation to intensive chemotherapy for acute myeloid leukaemia in first remission: results of MRC AML 10 trial. The Lancet 351:9104, 700-708
CrossRef254
Reginald A. Clift, C. Dean Buckner. (1998) Marrow Transplantation for Acute Myeloid Leukemia. Cancer Investigation 16:1, 53-61
CrossRef255
A.J. Croockewit, M.H. Bronchud, M.S. Aapro, M.J. Bargetzi, J. Crown, A. Gratwohl, W. Lange, H. Ludwig, G. Martinelli, R. Mertelsmann. (1997) A European perspective on haematopoietic growth factors in haemato-oncology: Report of an expert meeting of the EORTC. European Journal of Cancer 33:11, 1732-1746
CrossRef256
Andreas Lohri, Benoît Hille, Marisa Bacchi, Markus Fopp, Franzisca Joncourt, Jürgen Reuter, Thomas Cerny, Martin F. Fey, Richard Herrmann. (1997) Five putative drug resistance parameters (MDR1/P-glycoprotein, MDR-associated protein, glutathione-S-transferase, bcl-2 and topoisomerase IIα) in 57 newly diagnosed acute myeloid leukaemias. European Journal of Haematology 59:4, 206-215
CrossRef257
Peter de Nully Brown, Jesper Jurlander, Jens Pedersen-Bjergaard, M.Alan Victor, Christian H. Geisler. (1997) The prognostic significance of chromosomal analysis and immunophenotyping in 117 patients with de novo acute myeloid leukemia. Leukemia Research 21:10, 985-995
CrossRef258
RUTH LADENSTEIN, CHRISTINA PETERS, HELMUT GADNER. (1997) The Present Role of Bone Marrow and Stem Cell Transplantation in the Therapy of Children with Acute Leukemia. Annals of the New York Academy of Sciences 824:1 Challenges an, 38-64
CrossRef259
Hartmut Link, Hans-Jochem Kolb, Wolfram Ebell, Dieter Kurt Hossfeld, Axel Zander, Dietrich Niethammer, Hannes Wandt, Hans Grosse-Wilde, Ulrich W. Schaefer. (1997) Die Transplantation hämatopoetischer Stammzellen. Medizinische Klinik 92:9, 534-545
CrossRef260
J. M. Tangen, F. Wisløff, M. Abdelnoor, L. Brinch, I. M. Dahl, J. Lamvik, B. Ly, I. Nesthus. (1997) Survival in 86 patients, aged 15-60, with primary acute myelogenous leukemia, treated with a common program in the Norwegian health regions I, III, IV and V in the period 1990-1995. European Journal of Haematology 59:2, 110-114
CrossRef261
GAVIN CULL, JOHN IVEY, PETER CHASE, ROSANNA PICCIUTO, RICHARD HERRMANN, PAUL CANNELL. (1997) Collection and Recruitment of CD34+ Cells During Large-Volume Leukapheresis. Journal of Hematotherapy 6:4, 309-314
CrossRef262
R WILLEMZE, S SUCIU, F MANDELLI, T DEWITTE, S AMADORI, M HAYAT, M PETTI, G SOLBU, R ZITTOUN. (1997) New trends in the treatment of adult acute myeloid leukaemia. European Journal of Cancer 33, S7-S14
CrossRef263
Yves Beguin, Brieuc Sautois, Patricia Forget, Jean Bury, Georges Fillet. (1997) Long term follow-up of patients with acute myelogenous leukemia who received the daunorubicin, vincristine, and cytosine arabinoside regimen. Cancer 79:7, 1351-1354
CrossRef264
Anders Wahlin, Lorentz Brinch, Per Hörnsten, Stein A. Evensen, Gunnar Öberg, Bengt Simonsson, Michael Hedenus. (1997) Outcome of a multicenter treatment program including autologous or allogeneic bone marrow transplantation for de novo acute myeloid leukemia. European Journal of Haematology 58:4, 233-240
CrossRef265
Bob Löwenberg, Wim L. J. Van Putten, Augustin Ferrant, Gert Ossenkoppele, Edo Vellenga, Leo F. Verdonck, Alois Gratwohl, Marc A. Boogaerts. (1997) Peripheral blood progenitor cell transplantation as an alternative to autologous marrow transplantation in the treatment of acute myeloid leukemia. Stem Cells 15:S2, 177-181
CrossRef266
N. Cole, B.E. Gibson. (1997) High-dose cytosine arabinoside in the treatment of acute myeloid leukaemia. Blood Reviews 11:1, 39-45
CrossRef267
Olle Ringdén. (1997) Bone marrow transplantation using unrelated donors for haematological malignancies. Medical Oncology 14:1, 11-22
CrossRef268
Frank Hartmann, Michael Pfreundschuh. (1997) Onkologie ’96. Medizinische Klinik 92:2, 83-100
CrossRef269
AK Burnett, OB Eden. (1997) The treatment of acute leukaemia. The Lancet 349:9047, 270-275
CrossRef270
Maurice J. Wolin, Robert Peter Gale. (1997) Therapy of acute myelogenous leukemia: Understanding the question, understanding the answer. Leukemia Research 21:1, 3-8
CrossRef271
Larry D. Cripe. (1997) Adult acute leukemia. Current Problems in Cancer 21:1, 1-64
CrossRef272
B.J.P. Huntly, I.M. Franklin, M.J. Pippard. (1996) Unrelated bone-marrow transplantation in adults. Blood Reviews 10:4, 220-230
CrossRef273
Kenneth Cornetta, Edward F. Srour, Ann Moore, Amy Davidson, E. Randolph Broun, Robert Hromas, Robert C. Moen, Richard A. Morgan, Lorraine Rubin, W. French Anderson, Ronald Hoffman, Guido Tricot. (1996) Retroviral Gene Transfer in Autologous Bone Marrow Transplantation for Adult Acute Leukemia. Human Gene Therapy 7:11, 1323-1329
CrossRef274
Roberto Stasi, Adriano Venditti, Giovanni Del Poeta, Germano Aronica, Elisabetta Abruzzese, Francesco Pisani, Manrico Cecconi, Mario Masi, Sergio Amadori. (1996) High-dose chemotherapy in adult acute myeloid leukemia: Rationale and results. Leukemia Research 20:7, 535-549
CrossRef275
Ravindranath, Yaddanapudi, Yeager, Andrew M., Chang, Myron N., Steuber, C. Philip, Krischer, Jeffrey, Graham-Pole, John, Carroll, Andrew, Inoue, Susumu, Camitta, Bruce, Weinstein, Howard J., . (1996) Autologous Bone Marrow Transplantation versus Intensive Consolidation Chemotherapy for Acute Myeloid Leukemia in Childhood. New England Journal of Medicine 334:22, 1428-1434
Full Text276
M. Watson, R. Zittoun, E. Hall, G. Solbu, K. Wheatley. (1996) A modular questionnaire for the assessment of longterm quality of life in leukaemia patients: The MRC/EORTC QLQ-LEU. Quality of Life Research 5:1, 15-19
CrossRef277
K. Atkinson, K. Downs, A. Dodds, A. Concannon, S. Milliken. (1996) Five year leukaemia-free survival of 72% and 77% for early stage acute and chronic myeloid leukaemia treated by HLA-identical sibling bone marrow transplantation. Australian and New Zealand Journal of Medicine 26:1, 54-58
CrossRef278
Eero Niskanen. (1996) Autologous Stem Cell Transplantation in the Treatment of Cancer. Annals of Medicine 28:1, 57-62
CrossRef279
Kevin Imrie, Karel A. Dicke, Armand Keating. (1996) Autologous Bone Marrow Transplantation for Acute Myeloid Leukemia. Stem Cells 14:1, 69-78
CrossRef280
Fujimaro Takaku. (1995) Cytokines and bone marrow transplantation. Journal of Cancer Research and Clinical Oncology 121:12, 701-709
CrossRef281
Thomas D. Miale, Suebsuk Sirithorn, Syed Ahmed. (1995) Efficacy and toxicity of radiation in preparative regimens for pediatric stem cell transplantation. I: Clinical applications and therapeutic effects. Medical Oncology 12:4, 231-249
CrossRef282
NORBERT-CLAUDE GORIN. (1995) Stem Cell Transplantation in Acute Leukemia. Annals of the New York Academy of Sciences 770:1 Bone Marrow T, 262-287
CrossRef283
George Marcoullis, Jayesh Mehta, Jennie Treleaven. (1995) Autologous bone marrow and peripheral blood stem cell transplantation in haematological malignancies: current status. Medical Oncology 12:4, 209-218
CrossRef284
P. Vandenberghe, M. A. Boogaerts. (1995) Graft-versus-leukemia and graft-versus-lymphoma effects of allogeneic bone marrow transplantation and of allogeneic donor leukocyte transfusions. Annals of Hematology 71:5, 209-217
CrossRef285
G. Heil, P. S. Mitrou, D. Hoelzer, M. Freund, H. Link, G. Ehninger, B. Steinke, S. Öhl, H. Wandt, E. Fackler-Schwalbe, G. Schlimok, A. Lösch, W. Queißer, B. Löffler, W. Gaus, J. Högel, H. Heimpel, E. Kurrle. (1995) High-dose cytosine arabinoside and daunorubicin postremission therapy in adults with de novo acute myeloid leukemia. Annals of Hematology 71:5, 219-225
CrossRef286
Agostino Tafuri, Lidia de Felice, Angela Goodacre, Susanna Fenu, Maria Teresa Petrucci, Tiziana Valentini, Giuliana Alimena, Maria Concetta Petti, Giovanna Meloni, Franco Mandelli, Michael Andreeff. (1995) Interleukin-3 priming in acute myeloid leukaemia patients. British Journal of Haematology 91:1, 234-244
CrossRef287
(1995) Treatment of Acute Myelogenous Leukemia. New England Journal of Medicine 332:25, 1717-1719
Full Text288
Löwenberg, Bob, . (1995) Post-Remission Treatment of Acute Myelogenous Leukemia. New England Journal of Medicine 332:4, 260-262
Full Text
- Letters
